Review Article

Traditional Medicinal Uses, Phytoconstituents, Bioactivities, and Toxicities of *Erythrina abyssinica* Lam. ex DC. (Fabaceae): A Systematic Review

Samuel Baker Obakiro,1,2,3 Ambrose Kipro,2,3 Elizabeth Kigondu,1 Isaac K’Owino,5,3 Mark Peter Odero,2,3 Scolastica Manyim,2,3 Timothy Omara,2,3,6 Jane Namukobe,7 Richard Oriko Owor,8 Yahaya Gavamukulya,6,9 and Lydia Bunalema10

1Department of Pharmacology and Therapeutics, Faculty of Health Sciences, Busitema University, P.O. Box 1460, Mbale, Uganda
2Department of Chemistry and Biochemistry, School of Sciences and Aerospace Studies, Moi University, P.O. Box 3900-30100, Eldoret, Kenya
3Africa Centre of Excellence II in Phytochemicals, Textiles and Renewable Energy (ACE II PTRE), Moi University, P.O. Box 3900-30100, Eldoret, Kenya
4Centre of Traditional Medicine and Drug Research, Kenya Medical Research Institute, P.O. Box 54840-00200, Nairobi, Kenya
5Department of Pharmacology and Therapeutics, School of Biomedical Sciences, Makerere University College of Health Sciences, P.O. Box 7062, Kampala, Uganda
6Department of Pure and Applied Chemistry, Faculty of Science, Masinde-Muliro University, P.O. Box 190-50100, Kakamega, Kenya
7Department of Chemistry, School of Physical Sciences, College of Natural Sciences, Makerere University, P.O. Box 7062, Kampala, Uganda
8Department of Quality Control and Quality Assurance, Product Development Directory, AgroWays Uganda Limited, Plot 34-60, Kyabazinga Wny, P.O. Box 1924, Jinja, Uganda
9Department of Chemistry, Faculty of Science Education, Busitema University, P.O. Box 236, Tororo, Uganda

Correspondence should be addressed to Samuel Baker Obakiro; sobakiro@gmail.com

Received 12 January 2021; Revised 16 February 2021; Accepted 22 February 2021; Published 4 March 2021

Academic Editor: Riaz Ullah

Copyright © 2021 Samuel Baker Obakiro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Many studies have been undertaken on the medicinal values of *Erythrina abyssinica* Lam. ex DC. (Fabaceae). The details, however, are highly fragmented in different journals, libraries, and other publication media. This study was therefore conducted to provide a comprehensive report on its ethnobotany, ethnomedicinal uses, phytochemicals, and the available pharmacological evidence supporting its efficacy and safety in traditional medicine. Method. We collected data using a PROSPERO registered systematic review protocol on the ethnobotany, ethnomedicinal uses, phytochemicals, and the available pharmacological evidence supporting its efficacy and safety in traditional medicine. Results. *Erythrina abyssinica* is harvested by traditional herbal medicine practitioners in East, Central, and South African communities to prepare herbal remedies for various human and livestock ailments. These include bacterial and fungal infections, tuberculosis, malaria, HIV/AIDS, diarrhea, cancer, meningitis, inflammatory diseases, urinary tract infections, wounds, diabetes mellitus, and skin and soft tissue injuries. Different extracts and phytochemicals from parts of *E. abyssinica* have been scientifically proven to possess anti-inflammatory, antibacterial, antioxidant, antimplasmodial, antiproliferative, antifungal, antimycobacterial, antidiarrheal, anti-HIV 1, antidiabetic, and antiobesity activities. This versatile pharmacological activity is due to the abundant flavonoids,
Tropical Asia and Central America have East Africa but also found in Central and South Africa [8, 9]. Erythrina abyssinica flowers and branchesthat resemble the shape of seacoral[7]. The genus are usually referred to as "coral trees" due to their red epithet "abyssinica" means "from Ethiopia" [5]. The reflection of the showy red flowers of its various species. The common English names of E. abyssinica are coral tree, Uganda coral, kaffir boom, erythrina, flame tree, red-hot-poker tree, and lucky-bean tree [10]. Some of the local names used across indigenous communities are summarized in Table 1.

Medicinal plants have been a veritable source of cure for a number of human and livestock diseases, and thus, they are widely used in many communities. This is because plants house abundant secondary metabolites (phytochemicals) with potential pharmacological activities. These include flavonoids, alkaloids, terpenoids, phenols, chalcones, quinones, aromatic hydrocarbons, chromosomes, and coumarins. It is these phytochemicals that are locally extracted in herbal preparations and used as remedies for the management of several diseases. The World Health Organization (WHO) estimated that 80% of the world’s population especially in low- and middle-income countries rely on herbal medicines for primary health care [30]. The use of herbal medicines in the management of several ailments among people continues to gain momentum due to their availability, affordability, perceived effectiveness, and cultural acceptability across ethnic backgrounds [31].

Globally, there has been an increase in natural product research in the last two decades [30, 32]. This has been partly in response to the increasing antimicrobial resistance, emergence of new diseases, and decrease in the chemical diversity of natural product libraries [30, 32–36]. It has also been so in an effort to continue the search for more effective, safer, and cheaper therapeutic agents for existing diseases, to substitute expensive prescription drugs [37–40]. Erythrina abyssinica is among those revered plants [40, 41] that has been widely researched [3]. However, the information on it is highly fragmented in different journals, books, university libraries, and other publication media platforms. This review was therefore undertaken to compile a comprehensive document that describes the ethnobotany, phytochemistry, and ethnopharmacology of E. abyssinica so as to generate integrated and sufficient scientific evidence to support its medicinal use. The study further emphasizes the importance of conserving this medicinal plant amidst the growing destruction of natural resources for settlement, industrialization, construction, and energy production [27, 42–47].

1. Introduction

Erythrina abyssinica Lam. ex DC. (Fabaceae) is an important medicinal plant as evidenced by the existence of its names in various local languages and high frequency of citation in ethnobotanical surveys [1–4]. The genus Erythrina derives from the Greek word “erythros,” translated to mean red (a reflection of the showy red flowers of its various species). The epithet “abyssinica” means “from Ethiopia” [5]. The Erythrina genus houses at least 120 species distributed mainly in tropical and subtropical zones [6]. Plants in this genus are usually referred to as “coral trees” due to their red flowers and branches that resemble the shape of sea coral [7]. Erythrina abyssinica is a deciduous leguminous tree native to East Africa but also found in Central and South Africa [8, 9]. Tropical Asia and Central America have E. abyssinica as an exotic species. The common English names of E. abyssinica are coral tree, Uganda coral, kaffir boom, erythrina, flame tree, red-hot-poker tree, and lucky-bean tree [10]. Some of the local names used across indigenous communities are summarized in Table 1.

Medicinal plants have been a veritable source of cure for a number of human and livestock diseases, and thus, they are widely used in many communities. This is because plants house abundant secondary metabolites (phytochemicals) with potential pharmacological activities. These include flavonoids, alkaloids, terpenoids, phenols, chalcones, quinones, aromatic hydrocarbons, chromosomes, and coumarins. It is these phytochemicals that are locally extracted in herbal preparations and used as remedies for the management of several diseases. The World Health Organization (WHO) estimated that 80% of the world’s population especially in low- and middle-income countries rely on herbal medicines for primary health care [30]. The use of herbal medicines in the management of several ailments among people continues to gain momentum due to their availability, affordability, perceived effectiveness, and cultural acceptability across ethnic backgrounds [31].

Globally, there has been an increase in natural product research in the last two decades [30, 32]. This has been partly in response to the increasing antimicrobial resistance, emergence of new diseases, and decrease in the chemical diversity of natural product libraries [30, 32–36]. It has also been so in an effort to continue the search for more effective, safer, and cheaper therapeutic agents for existing diseases, to substitute expensive prescription drugs [37–40]. Erythrina abyssinica is among those revered plants [40, 41] that has been widely researched [3]. However, the information on it is highly fragmented in different journals, books, university libraries, and other publication media platforms. This review was therefore undertaken to compile a comprehensive document that describes the ethnobotany, phytochemistry, and ethnopharmacology of E. abyssinica so as to generate integrated and sufficient scientific evidence to support its medicinal use. The study further emphasizes the importance of conserving this medicinal plant amidst the growing destruction of natural resources for settlement, industrialization, construction, and energy production [27, 42–47].

2. Methods

2.1. Protocol Registration and Reporting. The protocol used in this systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) and can be accessed from their website (https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020187081) with the registration number CRD42020187081. The Preferred Reporting Items for the Systematic Reviews and Meta-Analyses (PRISMA) guidelines [48] have been used in the reporting of this study (Figure 1).

2.2. Literature Search. Electronic data on ethnobotany, phytochemistry, efficacy, and toxicity of E. abyssinica were retrieved from electronic databases such as Scopus, Web of Science Core Collection, PubMed, American Chemical Society, ScienceDirect, Scientific Electronic Library Online (SciELO), Google Scholar, and NAPRALERT (a comprehensive natural products database with ethnomedical and pharmacological information of extracts and isolated compounds). Sets of keywords such as "ethnobotany," "traditional medicine," "ethnobotany," "alternative medicine," "ethnopharmacology," "phytochemistry," "extraction," "isolation," "efficacy," "safety," "toxicity," "phytochemicals," "structural elucidation," and clinical study were combined with "Erythrina abyssinica." The retrieved articles were downloaded and stored in EndNote X9 (Thomson Reuters, San Francisco, CA, USA) by three independent authors (SBO, TO, and YG). Duplicate articles were then removed from the file. Further, manual search from the reference lists of screened eligible articles and deposited electronic copies of dissertations and theses in University online libraries were done. The authors continuously received notifications of any new "similar reports" meeting the search criteria from ScienceDirect, Scopus, and Google Scholar.

2.3. Screening. Retrieved articles were first screened based on the titles and abstracts for relevance to the study by three independent reviewers (MPO, SM, and YG). Articles that reported on other species of Erythrina but not abyssinica and
Records a/f ter duplicates removed (n = 802)

Records excluded based on titles and abstracts (n = 601)

Full-text articles assessed for eligibility (n = 201)

Full-text articles excluded, with reasons (n = 39) articles not in English or French (n = 8) review articles (n = 11) did not rovide an data (n = 22)

Full-text articles assessed for eligibility (n = 121)

Full-text articles retrieved from reference list check through manual search (n = 11)

Studies included in the review (n = 132)

Figure 1: PRISMA flow diagram showing the search and retrieval steps of the study (adopted from Moher et al. [48]).
also abyssinica but not of genus Erythrina were also excluded. For example, we excluded articles on Entada abyssinica, Erythrina variageta, Erythrina suberosa, Albuca abyssinica, Dregea abyssinica, Harrisonia abyssinica, and Wahlenbergia abyssinica although they appeared in the search results. During the screening, every time a disagreement occurred it was resolved through a discussion between the reviewers and/or by the principal investigator (SBO). The eligible articles were then assessed further for inclusion in the study using the inclusion/exclusion criteria.

2.4. Inclusion and Exclusion Criteria. Full-text articles that at least reported on ethnobotany, ethnopharmacology, and phytochemistry of Erythrina abyssinica written in English or French but translated to English and published in peer-reviewed journals, reports, books, theses, and dissertations dated until January 2021 were considered. All publishing years were included without any geographical restrictions. Articles that reported data not relevant to the study, reviews, and not written in English or French were excluded from the study.

2.5. Data Extraction. A data collection tool was designed in Microsoft Excel (Microsoft Corporation, USA) to capture data on different aspects of E. abyssinica. Three reviewers independently extracted relevant data from the included articles regarding the ethnobotany, ethnopharmacology, and phytochemistry of E. abyssinica. For ethnobotanical data, the diseases or ailments managed, parts used, and mode of preparation and administration were captured. For phytochemistry, the name of isolated pure compounds, chemical class, extraction solvent, and their efficacy and toxicity were captured. For ethnopharmacology, extraction solvent used, bioassay/model used, results of efficacy, and toxicity of extracts were captured. The collected data were checked for completeness and processed independently by two reviewers.

2.6. Data Analysis and Synthesis. Descriptive statistical methods were used to analyse the collected data. Results were expressed as percentages and frequencies and subsequently presented as tables and charts. The analyses were performed using SPSS statistical software (version 20, IBM Inc.).

3. Results and Discussion

3.1. Literature Search and Publications. A total of 201 reports were retrieved out of which 132 met the inclusion criteria and were reviewed. Of these, 78 articles reported only on the ethnobotany, 27 articles on pharmacology only, 15 articles on both ethnobotany and pharmacology, 5 articles on phytochemistry only, and 3 articles on both ethnobotany and pharmacology while 4 articles on ethnobotany, pharmacology, and phytochemistry. Most of the articles (56.8%) were published in the 2010–2019 decade, indicating a lot of research is being done as compared to the preceding decades (Figure 2). This could be due to the (1) growing need for more effective and less toxic medicinal products of plant origin, (2) emerging antimicrobial resistance that has rendered most chemotherapeutic agents less effective, (3) new disease outbreaks like Ebola, and (4) increase in non-communicable diseases such as cancers, hypertension, diabetes mellitus, and sexual dysfunction that require readily available, affordable, effective, and safe therapies.

3.2. Taxonomy, Morphology, Distribution, and Propagation. Erythrina abyssinica belongs to the kingdom Plantae, phylum Spermatophyta, subphylum Magnoliophyta (flowering plants), class Magnoliopsida (dicotyledons), order Fabales, family Fabaceae (legumes), subfamily Papilionoideae, genus Erythrina (L.), and species abyssinica (Lam ex. DC.). The frequently encountered synonyms of this species include E. kassneri Baker f., Corallodendron suberifera (Welw. ex Baker) Kuntze, E. bequaerti De Wild., E. tomentosa R. Br., Chirocalyx abyssinicus (Lam.) Hochst., and C. tomentosus Hochst. [3].

Erythrina abyssinica grows as a multibranched deciduous tree or shrub up to a height of 12–15 m tall usually with a rounded spreading crown (Figure 3). The branches have a corky thick deeply fissured bark with prickles (4–8 mm long). The leaves are trifoliate alternately arranged with long (6–20 cm) petiole. The leaflets can be ovate, cordate, and almost circular, rounded at the base and obtuse or notched at the apex, with network venation, dense hair usually at the abaxial surface, and prickles [49, 50]. The inflorescence is raceme, dense, pyramidal, and either terminal or axial with a long peduncle (up to 20 cm) and caducous bracts. Flowers are bisexual and papilionaceous having densely hairy, cylindrical, split at one side calyx, brightly coloured (orange to red) corolla with free keel petals, 10 fused and one free stamen, one carpel with a superior cylindrical oblong ovary, long style, and flat stigma head [51]. The fruits are linear-oblong pods, brown to black in colour, usually hairy, dehisce at two values to release ellipsoid, long (6–12 mm), and bright red seeds [52]. The tree is anchored firmly in the ground by a deep root system [13, 20].

Erythrina abyssinica can be propagated either using seeds, wildings [40], or cuttings, but the former has comparatively lower germination rates of 10–30% with propagation restricted to rainy seasons [3, 11, 53]. It grows naturally in woodland and wooded grasslands (savannah woodlands, grasslands, and scrublands, secondary scrub vegetation, regions with 500–2000 mm annual rainfall and optimal temperatures of 15–25°C) [11, 54–57]. Thus, it is widespread from Sudan, South Sudan, Uganda, Kenya, Rwanda, Burundi, Democratic Republic of Congo, Congo (Brazzaville), Tanzania to Ethiopia, Eritrea, Angola, Namibia, Botswana, Central African Republic, Swaziland, Lesotho, Gabon, Zambia, Zimbabwe, and Mozambique (Figure 4) [3, 10, 11, 53]. It has also been introduced as an ornamental in Mauritius and various places in Tropical Asia and Central America, including Afghanistan, Bangladesh, Bhutan, India, Nepal, Pakistan, and Sri Lanka [10, 53]. In South Sudan for instance, the tree grows at up to 2000 m
altitude while in Tanzania, they are found at up to 2300 m. The tree naturally grows on loamy to clay soils, with preference for deep well-drained soils on plateaus and slopes with a pH of 3.5–5.5. The tree is termite- and fire-resistant primarily due to its deep root system but cannot tolerate frost, explaining its limited distribution in cold regions [11, 53].

3.3. Ecological, Traditional, and Medicinal Uses. *Erythrina abyssinica* being a legume is well known for fixing nitrogen into the soil and thus enhances soil fertility. Because of this, it plays an important role in phytorestoration and forest regeneration in polluted soils [64–66]. Its flowers also secrete nectar that is fed on by pollinating insects especially bees hence being important in both horticulture and apiculture [67]. Although this plant usually grows naturally in the wild, some communities cultivate it in their homesteads as an ornamental plant, for live fencing purposes due to its brightly coloured flowers and prickles, a material for dye, and craft materials such as curios and necklaces (from seeds) [9, 20, 68, 69]. The stem of this plant is also harvested to obtain timber and charcoal for furniture and energy purposes, respectively [20]. In livestock farming, the plant leaves are used as fodder for animals [5, 70, 71].

The stem bark, seeds, roots, root bark, leaves, and flowers of *E. abyssinica* and the whole plant either in combination or
singly are used to prepare herbal remedies for various human ailments (Table 2). However, the stem bark and roots are the most commonly used parts in the preparation of herbal remedies. Even in efficacy, toxicity, and phytochemical studies, the stem bark and roots were the most investigated. This could probably be due to high yield associated with them because of their high potential in concentrating and storing phytochemicals. The seeds were indicated to be poisonous when crushed [11]. The commonest methods of preparation and administration of herbal medicines from this plant are boiling (decoctions) and then drinking, cold infusions (taken orally), pounding dried samples into powder and then licking, pounding fresh samples into a paste and applying topically, squeezing fresh samples and mixing with bathing water, or direct chewing of the different parts (Table 2).

Among the frequently reported ailments for which herbal medicines containing *E. abyssinica* are used include bacterial and fungal infections, malaria, leprosy, tuberculosis (cough), inflammatory diseases, HIV/AIDS, cancer, and metabolic disorders such as diabetes mellitus, obesity, and anaemia. Other conditions treated using this plant include snake bites, antagonizing poisons, venereal diseases (sexually transmitted diseases, e.g., gonorrhea, syphilis, and urinary tract infections including schistosomiasis), soft tissue and skin infections, diarrhea, infertility and pregnancy-related conditions, pneumonia, epilepsy, central nervous system- (CNS-) related disorders, vomitings, hepatitis, and helminthiasis. In ethnoveterinary medicine, extracts of *E. abyssinica* are used in the management of poultry and livestock diseases such as newcastle disease, anaplasmosis, and helminthosis [43, 89, 119, 123, 124].

### 3.4. Phytochemical Profile of *E. abyssinica*

#### 3.4.1. Preliminary Phytochemical Analyses

Qualitative phytochemical screening of medicinal plants is an essential step to their detailed phytochemical and pharmacological investigation [125]. Preliminary phytochemical screening of different solvent extracts of *E. abyssinica* indicated the presence of tannins, saponins, alkaloids, and flavonoids as the main therapeutic secondary metabolites (Table 3).

#### 3.4.2. Structural Elucidation

Like in many natural product research studies, chromatography has been used in the isolation of compounds from crude extracts of *E. abyssinica*. The most widely used techniques included high-performance liquid chromatography (HPLC), gas chromatography (GC), high-performance thin-layer chromatography (HPTLC), and ultraperformance liquid chromatography (UPLC) [129]. Spectroscopic techniques such as mass spectrometry (MS), ultraviolet (UV) spectrophotometry, one-dimensional nuclear magnetic resonance (1D-NMR) spectroscopy, and its complementary techniques (heteronuclear multiple bond correlation (HMBC) spectroscopy, heteronuclear multiple quantum coherence (HMQC) spectroscopy, nuclear overhauser effect spectroscopy (NOESY), and circular dichroism (CD) spectroscopy) have been used to elucidate chemical structures of the isolated compounds [130]. Chromatography-spectroscopy hyphenated techniques have become more commonly used in recent decades due to the increased efficiency, sensitivity, and detection limits [1]. These include LC-MS, GC-MS, UPLC-MS, HPTLC-UV, HPLC-photodiode array detection, LC-

![Figure 4: Native geographical distribution of *E. abyssinica* (based on retrieved literature [4, 10, 11, 15, 21, 23–25, 27–29, 58–63]).](image-url)
| No. | Disease/ailments treated                      | Parts used | Method of preparation and administration                                                                 | Country                                      | Authors                                                                 |
|-----|---------------------------------------------|------------|----------------------------------------------------------------------------------------------------------|---------------------------------------------|------------------------------------------------------------------------|
| 1   | Malaria, fevers                             | R, SB, L, F | Boiled and taken orally                                                                                  | Uganda, Kenya, Tanzania, Ethiopia, Eritrea, DR Congo, Sudan, Rwanda | [9, 13, 18, 21, 24, 28, 58, 72–82]                                      |
| 2   | Inflammatory disorders, eye problems, and pain | SB, R, Sd  | Boiled and taken orally; powdered, mixed with petroleum jelly, and smeared on the wound/swollen part. For eye problems, it is applied as liniment | Uganda, Tanzania, Kenya, South Sudan Sudan | [13, 19, 20, 27, 72, 83–88]                                            |
| 3   | Bacterial and fungal infections              | SB, L, F, WP| Boiled and taken orally; powdered and licked; sliced bark chewed; cold infusion taken orally                | Uganda, Kenya, Burundi                     | [13, 72, 89–91]                                                        |
| 4   | Skin and soft tissue infections, leprosy, and wounds | SB, F, L  | Boiled in petroleum jelly and smeared at the tissue, herbal bath of infected skin part                     | Uganda, Kenya, Zimbabwe, Rwanda            | [20, 24, 72, 81, 87, 92–95]                                            |
| 5   | Tuberculosis (cough)                         | SB, R, L, F| Decoction taken orally; powdered and licked                                                              | Uganda, Kenya, Tanzania, Burundi, Zimbabwe | [31, 61, 72, 73, 95–99]                                                |
| 6   | Cancer                                      | SB, L, F   | Boiled and taken orally                                                                                    | Uganda, Kenya                             | [39, 72, 100]                                                          |
| 7   | HIV/AIDS                                    | SB, R      | Decoction taken orally                                                                                   | Uganda, Kenya                             | [2, 39, 72, 98, 101–103]                                               |
| 8   | Infertility, birth control, pregnancy related conditions | SB, R     | Decoction, squeezing, chewing, taken orally                                                              | Uganda, Kenya                             | [31, 72, 73, 104–106]                                                 |
| 9   | Blood disorders (anaemia and jaundice)       | R, SB, L, F| Boiled and taken orally                                                                                    | Uganda, Kenya, Tanzania                   | [27, 31, 72, 84, 107–109]                                              |
| 10  | Venereal diseases                           | SB, L, F, RB| Boiled and taken orally                                                                                   | Uganda, Kenya, Zimbabwe, Rwanda           | [19, 20, 63, 72, 87, 92, 100, 105, 110–112]                            |
| 11  | Diabetes mellitus                           | SB, L      | Boiled and taken orally                                                                                    | Rwanda                                     | [72, 113, 114]                                                        |
| 12  | Hepatitis, measles, scabies, herpes, mumps, liver diseases | SB, R, L   | Boiled and taken orally                                                                                    | Rwanda, Kenya, Uganda                      | [22, 23, 101, 115]                                                    |
| 13  | Pneumonia                                   | SB         | Boiled in water and taken orally                                                                          | Kenya                                     | [92, 100]                                                              |
| 14  | Convulsions and CNS disorders               | SB         | Decoction, pound, and add salt                                                                           | Uganda                                    | [31]                                                                   |
| 15  | Gastrointestinal disorders (diarrhea, stomach ache, vomiting, constipation, ulcers, dysentery, colic) | SB, R, L   | Boiled, honey added, and taken orally. Decoction taken, or pounded, salt added, and taken. Root decoction with Rhamnus prinoides roots taken for colic. Decoction of young roots taken for constipation in children | Uganda, Kenya, Tanzania, Eritrea, Angola, Rwanda | [4, 19, 26, 31, 87, 92, 101, 106, 107, 116–118]                          |
| 16  | Helminthiasis                               | SB         | Decoction taken orally                                                                                    | Uganda, Kenya, Tanzania                   | [87, 105, 119, 120]                                                    |
| 17  | Snake bites/antidote for poisoning           | R, SB, RB  | Sap used/pounded and applied at the bite. Boiled and taken orally                                         | Uganda, Kenya, Tanzania                   | [15, 16, 19, 109, 121, 122]                                             |

Parts used: L: leaves, R: roots, RB: root bark, Sd: seeds, SB: stem bark, F: flowers, and WP: whole plant.
NMR-MS, GC-NMR-MS, and high-resolution electron spray ionization (ESI)-MS [130].

A total of 122 phytochemicals which are primarily alkaloids, flavonoids, and triterpenoids have been isolated from *E. abyssinica* (Figure 5; Table 4). Some of the isolated compounds are specific to *E. abyssinica* while others have been reported to be present in other species of the genus *Erythrina* [149]. Because genus *Erythrina* belongs to the family Fabaceae, its members have a rich diversity of secondary metabolites (phytochemicals) amongst themselves due to possession of various biosynthetic pathways [150]. However, some species share common phytochemicals, and hence, these act as biomarkers for nutraceutical, pharmaceutical, and toxicological potentials in the food and drug industries [130, 151].

(1) Alkaloids. In the present study, we retrieved thirteen alkaloids (1–12 and 95) that have been isolated from *E. abyssinica* (Table 4, Figure 5). The *Erythrina* alkaloids have a tetracyclic carbon skeleton with three rings (A, B, and C) common to all the alkaloids and the fourth ring (D) which varies among the different alkaloids [1, 152]. Lactonic alkaloids contain ring D as an unsaturated δ-lactone, dienoid alkaloids possess a benzenoid ring D (with two double bonds at C-1 and C-2, and C-6 and C-7), and alkenoid alkaloid possess a benzenoid ring D with a double bond between C-1 and C-6. Aromatic alkaloids and those containing a double bond at C-16 undergo stereoisomerism to give rise to other alkaloid derivatives [152].

(2) Flavonoids. A total of 106 flavonoids have been isolated and identified from *E. abyssinica*. These include five benzofurans, six chalcones, two coumestans, six isoflavones and seventy-two flavanones, four flavones, and eleven pterocarps.

(i) Benzofurans. Benzofurans are heterocyclic compounds consisting of benzene and furan rings fused together. Five benzofurans (65–69) have been isolated from the stem bark of *E. abyssinica* [144].

(ii) Chalcones. Chalcones, also known as chalconoids or benzyl acetophenones, are α, β-unsaturated ketones made up of two aromatic rings (designated as rings A and B) with diverse substituents. They possess conjugated double bonds and a completely delocalized π-electron system on both benzene rings. Chalcones have been widely known in medicinal chemistry as potential templates for the synthesis of therapeutic agents [153]. In this study, seven chalcones (15, 28–32, and 47) were retrieved to have been isolated from the roots and stem bark of *E. abyssinica*.

(iii) Coumestans. Coumestans are oxidized derivatives of pterocarpan consisting of a benzoxole fused to a chromen-2-one to form 1-benzoxolo[3,2-c]chromen-6-one. They are responsible for the phytoestrogenic activity of most medicinal plants of the family Fabaceae [154]. Two coumestans, erythrybysin N (62) and isosojagol (64), were isolated from the stem bark of *E. abyssinica*.

(iv) Isoflavones and Flavanones. Isoflavones are a large group of flavonoids possessing a 3-phenylchroman skeleton that is biosynthetically obtained by rearrangement of the 2-phenylchroman flavonoid system. They are naturally occurring exclusively in the family Fabaceae (Leguminosae). Differences among isoflavones arise from the presence of extra heterocyclic rings, different oxidation states in this skeleton, and the number of substituents on the isoflavone moiety [155]. On the other hand, flavanones have the basic 2,3-dihydroflavone structure. They are distinguished from the rest of the flavonoid class by the lack of a double bond between C-2 and C-3 and the presence of a chiral center at C-2 position. Members differ from one another in the position and/or the number of the constituent methoxy and hydroxyl substituents [156]. Unlike isoflavones, flavanones are naturally occurring in members of family Fabaceae, Compositae, and Rutaceae. A total of six isoflavones (25–27, 83, 110, and 111) and 72 flavanones (14, 17–22, 24, 33–46, 48–61, 63, 70–75, 77–82, 84, 87–92, 100–103, 108, 109, 118–119, and 121–122) have been isolated from *E. abyssinica* root bark, stem bark, and roots.

(v) Pterocarps. Pterocarps are structural analogs to isoflavonoids with a benzofurochromene skeleton. They can also be derived from coumestans through reduction reactions. They have two asymmetric centers at C-6a and C-11a and may exist as cis or...
Figure 5: Continued.
22

23 \( R_1 = R_2 = H, R_3 = \text{OH}, R_4 = \text{OCH}_3, R_5 = \text{prenyl} \)

24 \( R_1 = R_4 = R_5 = \text{OH}, R_2 = R_3 = \text{Prenyl} \)

25

26

27

28

29

30

31

32

33 \( R_1 = \text{prenyl}, R_2 = \text{OH}, R_3 = \text{CH}_3 \)

34 \( R_1 = \text{H}, R_2 = \text{OH}, R_3 = \text{CH}_2\text{OH} \)

35 \( R_1 = \text{H}, R_2 = \text{OCH}_3, R_3 = \text{CH}_2\text{OH} \)

36

\( \text{R}_1 = \text{R}_2 = \text{H}, \text{R}_3 = \text{OH}, \text{R}_4 = \text{OCH}_3, \text{R}_5 = \text{prenyl} \)

(b)
37 R₁ = R₂ = OH, R₃ = R₄ = H, R₅ = prenyl
38 R₁ = R₂ = OH, R₃ = R₄ = H, R₅ = OCH₃
39 R₁ = R₂ = OH, R₃ = R₄ = H
40 R₁ = R₂ = OH, R₃ = H, R₄ = prenyl
41 R₁ = R₂ = RH, R₃ = prenyl, R₄ = OH
42 R₁ = R₂ = R₃ = OH, R₄ = H, R₅ = ( = 0)
43 R₁ = R₂ = R₃ = H, R₄ = R₅ = OH
44 R₁ = R₂ = H, R₃ = R₄ = R₅ = OH

(c) **Figure 5:** Continued.
(d)

Figure 5: Continued.
Figure 5: Continued.
Figure 5: Continued.
Figure 5: Chemical structures of the phytochemicals isolated from *E. abyssinica*. The numbers: 1–122 correspond to compounds mentioned in Table 4.
| Name of the compound identified | Chemical class | Part used | Solvent used | Techniques used | Bioactivity tested | Result | Authors |
|---------------------------------|---------------|-----------|--------------|-----------------|-------------------|--------|---------|
| (+)-Erysotrine (1)              | Alkaloid      | NS        | NS           | NMR             | Not tested        | Not applicable | [131]   |
| (+)-Erythravine (2)             | Alkaloid      | NS        | NS           | NMR             | Not tested        | Not applicable | [131]   |
| (+)-Erythristemine (3)          | Alkaloid      | NS        | NS           | NMR             | Not tested        | Not applicable | [131]   |
| (+)-Erysovine (4)               | Alkaloid      | NS        | NS           | NMR             | Not tested        | Not applicable | [131]   |
| (+)-Erysovinine (5)             | Alkaloid      | Sd        | Chloroform, ethanol | NMR         | Curare-like activity | Strong activity | [131, 132] |
| (+)-Erysovinine (6)             | Alkaloid      | Sd        | Chloroform, ethanol | NMR         | Curare-like activity | Strong activity | [131, 132] |
| (+)-Erythraline (7)             | Alkaloid      | NS        | NS           | NMR             | Not tested        | Not applicable | [131]   |
| (+)-8-Oxoerythraline (8)        | Alkaloid      | NS        | NS           | NMR             | Not tested        | Not applicable | [131]   |
| (+)-11-Oxoerysovinine (9)       | Alkaloid      | NS        | NS           | NMR             | Not tested        | Not applicable | [131]   |
| (+)-11-Methoxyerysovinine (10)  | Alkaloid      | NS        | NS           | NMR             | Not tested        | Not applicable | [131]   |
| (+)-Erythratidine (11)          | Alkaloid      | NS        | NS           | NMR             | Not tested        | Not applicable | [131]   |
| (+)-Erythratine (12)            | Alkaloid      | NS        | NS           | NMR             | Not tested        | Not applicable | [131]   |
| 8-Methoxyneorautenol (13)       | Pterocarpan   | RB        | Acetone      | HRMS, NMR, HMBC | Radical scavenging properties | Moderately active | [133] |
| Eryvarin L (14)                 | Benzofuran    | Rt        | Chloroform: methanol (1 : 1) Chloroform: methanol (1 : 1) | UV, NMR, EI-MS, NMR, HMBC | Antimicrobial and antioxidant activities | Good antioxidant activity | [134] |
| Licoagrochalcone A (15)         | Chalcone      | Tw        | Chloroform: methanol (1 : 1) | UV, NMR, EI-MS, NMR, HMBC | PTP 1B inhibitory activity | No activity | [135] |
| 3-Hydroxy-9-methoxy-10-(3,3-dimethylallyl) pterocarpane (16) | Pterocarpan | RB | Acetone | UV, HPLC, NMR, HMBC | PTP 1B inhibitory activity | No activity | [135] |
| (2S)-5,7-Dihydroxy-3′-prenyl-2″ξ-(4″-hydroxyisopropyl)-3″'-hydroxy-dihydrofurano[1″,3″':4′,5″'] flavanone (17) | Flavanone | SB | Methanol | UV, HPLC, NMR, HMBC | PTP 1B inhibitory activity | No activity | [135] |
| (2S)-5,7-Dihydroxy-3′-methoxy-2″ξ-(4″-hydroxyisopropyl)-3″'-hydroxy-dihydrofurano[1″,3″':4′,5″'] flavanone (18) | Flavanone | SB | Methanol | UV, HPLC, NMR, HMBC | PTP 1B inhibitory activity | No activity | [135] |
| (2S)-5,7-Dihydroxy-3′-methoxy-2″ξ-(4″-hydroxyisopropyl)-3″'-hydroxy-dihydrofurano[1″,3″':4′,5″'] flavanone (19) | Flavanone | SB | Methanol | UV, HPLC, NMR, HMBC | PTP 1B inhibitory activity | No activity | [135] |
| Name of the compound identified | Chemical class | Part used | Solvent used | Techniques used | Bioactivity tested | Result | Authors |
|---------------------------------|----------------|-----------|--------------|-----------------|-------------------|--------|---------|
| (2S)-5,7,3′-Trihydroxy-2″-hydroxyisopropyl-dihydrofurano[1″,3″:4′,5′] flavanone (20) | Flavanone SB | Methanol | UV, HPLC, NMR, HMQC, HMBC | PTP 1B inhibitory activity | No activity | [135] |
| (2S)-5,7,3′-Trihydroxy-2″-hydroxy-dihydrofurano[1″,3″:4′,5′] flavanone (21) | Flavanone SB | Methanol | UV, HPLC, NMR, HMQC, HMBC | PTP 1B inhibitory activity | No activity | [135] |
| Erythrabyssin I (22) | Pterocarpan | Rt | Methanol | UV, NMR, HPLC | Antimicrobial activity | Moderate | [136] |
| Erylatisin C (23) | Flavanone SB | Methanol | UV, HPLC, NMR, HMQC, HMBC | PTP 1B inhibitory activity | No activity | [135] |
| Abyssinin III (24) | Flavanone SB | Methanol | HREI-MS, HMQC, HMBC, NOESY | Not tested | Not applicable | [82] |
| Indicanine B (25) | Coumarin RB | DCM: MeOH | FTIR, UV, EI-MS, NMR | Antimicrobial activity | Active | [137] |
| Indicanine C (26) | Isoflavone RB | DCM: MeOH | FTIR, UV, EI-MS, NMR | Antimicrobial activity | Not active | [137] |
| Cajanan (27) | Isoflavone RB | DCM: MeOH | FTIR, UV, EI-MS, NMR | Antimicrobial activity | Not active | [137] |
| Abyssinone A (28) | Chalcone SB | Methanol | UV, CD, NMR, HRMS | Not tested | Not applicable | [138] |
| Abyssinone B (29) | Chalcone SB | Methanol | UV, CD, NMR, HRMS | Not tested | Not applicable | [138] |
| Abyssinone C (30) | Chalcone SB | Methanol | UV, CD, NMR, HRMS | Not tested | Not applicable | [138] |
| Abyssinone D (31) | Chalcone SB | Methanol | UV, CD, NMR, HRMS | Not tested | Not applicable | [138] |
| 3-Methylbutein (32) | Chalcone Rt | Chloroform: methanol (1:1) | UV, NMR, EI-MS, HMBC | Antimicrobial and antioxidant activities | Good bioactivities | [134] |
| 2(S)-5,5′,7′-Trihydroxy-2′-prenyl-(2″,2″-dimethylpyrano)-(3″,6″:3′,4′)flavanone (33) | Flavanone SB | Methanol | UV, CD, NMR, HRMS | PTP 1B inhibitory activity | Good activity | [138] |
| i2(S)-5,5′,7′-Trihydroxy-2″-(5″-hydroxy)-methylpyrano-(5″,6′:3′,4′)flavanone (34) | Flavanone SB | Methanol | UV, CD, NMR, HRMS | PTP 1B inhibitory activity | No activity | [138] |
| Name of the compound identified | Chemical class | Part used | Solvent used | Techniques used | Bioactivity tested | Result | Authors |
|--------------------------------|----------------|-----------|--------------|-----------------|-------------------|--------|---------|
| 2(S)-5,7-Dihydroxy-3′-methoxy-[2′-(5′-hydroxy)-methylpyrano]-,(5′,6′;3′,4′)flavanone (35) | Flavanone SB | Methanol | UV, CD, NMR, HRMS | PTP 1B inhibitory activity | Good activity | [138] |
| 2(S)-5,7-Dihydroxy-[5′,6′;3′,4′)-(2′,2″-dimethylpyrano)-(5″,6″;5′,6′)-(2″,2″-dimethylpyrano)flavanone (36) | Flavanone SB | Methanol | UV, CD, NMR, HRMS | PTP 1B inhibitory activity | No activity | [138] |
| 2(S)-5,7-Dihydroxy-5′-prenyl-[2″,2″-(3″-hydroxy)-dimethylpyrano]-,(5″,6″;5′,6″)-(3″,4″)flavanone (38) | Flavanone SB | Methanol | UV, CD, NMR, HRMS | PTP 1B inhibitory activity | Good activity | [138] |
| 2(S)-5,7-Dihydroxy-[2″,2″-(3″,4″-dihydroxy)-dimethylpyrano]-,(5″,6″;3′,4″)flavanone (39) | Flavanone SB | Methanol | UV, CD, NMR, HRMS | PTP 1B inhibitory activity | No activity | [138] |
| 2(S)-5,6′,7-Trihydroxy-5′-prenyl-[2″,2″-(3″,4″-dihydroxy)-dimethylpyrano]-,(5″,6″;3′,4″)flavanone (40) | Flavanone SB | Methanol | UV, CD, NMR, HRMS | PTP 1B inhibitory activity | Good activity | [138] |
| 2(S)-5,5′,7-Trihydroxy-[2″,2″-(4″-chromanone)-dimethylpyrano]-,(5″,6″;3′,4″)flavanone (41) | Flavanone SB | Methanol | UV, CD, NMR, HRMS | PTP 1B inhibitory activity | No activity | [138] |
| 2(S)-5,5′,7-Dihydroxy-[2″,2″-(3″-hydroxy)-dimethylpyrano]-,(5″,6″;3′,4″)flavanone (42) | Flavanone SB | Methanol | UV, CD, NMR, HRMS | PTP 1B inhibitory activity | No activity | [138] |
| 2(S)-5,5′,7-Dihydroxy-[2″,2″-(3″,4″-dihydroxy)-dimethylpyrano]-,(5″,6″;3′,4″)flavanone (44) | Flavanone SB | Methanol | UV, CD, NMR, HRMS | PTP 1B inhibitory activity | No activity | [138] |
| Abyssinin I (45) | Flavanone SB | Methanol | HPLC, NMR, HREI-MS, HMQC, HMBC, NOESY | Not tested | Not applicable | [82] |
| Abyssinin II (46) | Flavanone SB | Methanol | HPLC, NMR, HREI-MS, HMQC, HMBC, NOESY | Not tested | Not applicable | [82] |
| Name of the compound identified | Chemical class | Part used | Solvent used | Techniques used | Bioactivity tested | Result | Authors |
|---------------------------------|----------------|-----------|--------------|----------------|-------------------|--------|---------|
| Licochalcone A (47)             | Chalcone       | Rt        | Chloroform: methanol (1 : 1) | UV, NMR, EI-MS, HMBC, UV, HPLC, HREIMS, NMR, HMQC, HMBC, NOESY, UV, NMR, CD, HREIMS, HPLC, HMBC, NOESY, UV, NMR, CD, HREIMS, HPLC, HMBC, NOESY | Antimicrobial and antioxidant activities | Weak activity | [134] |
| Abyssinone V 4′-methyl ether (48) | Flavanone      | SB        | Methanol     | UV, HPLC       | Not tested         | Not applicable | [82] |
| Abyssinoflavanone IV (49)       | Prenylated flavanone | SB    | Methanol     | UV, NMR, CD, HREIMS, HPLC, HMBC, NOESY, UV, NMR, CD, HREIMS, HPLC, HMBC, NOESY | Not tested | Not applicable | [82, 138] |
| Abyssinoflavanone V (50)        | Prenylated flavanone | SB    | Methanol     | UV, NMR, CD, HREIMS, HPLC, HMBC, NOESY, UV, NMR, CD, HREIMS, HPLC, HMBC, NOESY | Not tested | Not applicable | [82, 138, 139] |
| Abyssinoflavanone VI (51)       | Prenylated flavanone | SB    | Methanol     | UV, NMR, CD, HREIMS, HPLC, HMBC, NOESY, UV, NMR, CD, HREIMS, HPLC, HMBC, NOESY | Not tested | Not applicable | [82, 138–140] |
| Sigmoidin D (52)                | Flavanone      | Rt, SB    | Chloroform: methanol (1 : 1), methanol | UV, NMR, CD, EI-MS, HRMS, HMBC | Antimicrobial and antioxidant activities, PTP 1B inhibitory activity | Weak activity | [82, 134, 138] |
| 5,7-Dihydroxy-2′,4′,5′-trimethoxyisoflavanone (53) | Isoflavanone | Rt        | Chloroform: methanol (1 : 1) | UV, NMR, CD, EI-MS, HMBC | Antimicrobial and antioxidant activities | Weak activity | [134] |
| 5-Prenylpratensein (54)         | Isoflavone     | Rt        | Methanol     | UV, HPLC | Antimicrobial activity | Moderate activity | [136, 139, 141] |
| Abyssinone I (55)               | Flavanone      | RB        | 80% aqueous MeOH, ether | UV, HPLC | Antimicrobial and PTP1B inhibitory activities | Moderate and no activity | [136, 141] |
| Abyssinone II (56)              | Flavanone      | RB        | MeOH, Ether | UV, HPLC | Antimicrobial activity | Moderate and no activity | [136, 141] |
| Abyssinone III (57)             | Flavanone      | RB        | Ethyl acetate | HPLC, IR, UV, MS, CD, NMR | PTP1B inhibitory and antifungal activities | Weak activity | [136, 142] |
| Abyssinone IV (58)              | Flavanone      | RB        | 80% aqueous MeOH, Chloroform: methanol (1 : 1) | UV, NMR, HMBC, EI-MS, HPLC, NMR | Antimicrobial and antioxidant activities | Moderate activity | [134, 136, 141] |
| Name of the compound identified | Chemical class | Part used | Solvent used | Techniques used | Bioactivity tested | Result | Authors |
|---------------------------------|----------------|-----------|--------------|-----------------|-------------------|--------|---------|
| Abyssinone V (59)               | Flavanone      | Rt, SB    | Chloroform : methanol (1 : 1) Methanol Ether Ethyl acetate | UV, NMR, HMBC, HREI-MS, CD, HPLC, NOESY | Antimicrobial, antiplasmodial, antioxidant, and PTP1B inhibitory activities | Weak activity [82, 134, 136, 141–143] |         |
| Abyssinone VI (60)              | Isoflavone     | NS        | Ether        | UV, HPLC        | Antifungal activity | Not reported [136] |         |
| Abyssinone VII (61)             | Chalcone       | Rt        | Chloroform : methanol (1 : 1), ether | UV, NMR, EI-MS, HMBC, HPLC | Antimicrobial and antioxidant activities | Good activity [134, 136] |         |
| Erythribyssin N (62)            | Benzofuran     | SB        | Methanol     | HPLC, IR, UV, MS, NMR, HPLC, IR, UV, MS, NMR | AMPK activity | Marked stimulation [144] |         |
| Sigmoidin K (63)                | Benzofuran     | SB        | Methanol     | HPLC, IR, UV, MS, NMR, HPLC, IR, UV, MS, NMR | AMPK activity | Marked stimulation [144] |         |
| Isosojagol (64)                 | Benzofuran     | SB        | Methanol     | HPLC, IR, UV, MS, NMR, HPLC, IR, UV, MS, NMR | AMPK activity | Less stimulation [144] |         |
| Erythribyssin F (65)            | Coumestan      | SB        | Methanol     | HPLC, IR, UV, MS, NMR, HPLC, IR, UV, MS, NMR | AMPK activity | Marked stimulation [144] |         |
| Eryvarin Q (66)                 | Coumestan      | SB        | Methanol     | HPLC, IR, UV, MS, NMR, HPLC, IR, UV, MS, NMR | AMPK activity | Less stimulation [144] |         |
| Erypoein F (67)                 | Coumestan      | SB        | Methanol     | HPLC, IR, UV, MS, NMR, HPLC, IR, UV, MS, NMR | AMPK activity | Marked stimulation [144] |         |
| Erythribyssin H (68)            | Benzofuran     | SB        | Methanol     | HPLC, IR, UV, MS, NMR, HPLC, IR, UV, MS, NMR | AMPK activity | Less stimulation [144] |         |
| Eryvarin R (69)                 | Benzofuran     | SB        | Methanol     | HPLC, IR, UV, MS, NMR, HPLC, IR, UV, MS, NMR | AMPK activity | Less stimulation [144] |         |
| Erythribyssin E (70)            | Isoflavanone   | RB        | Ethyl acetate | IR, UV, MS, CD, NMR | PTP 1B inhibitory activity | Strong activity [142] |         |
| Prostratol C (71)               | Isoflavanone   | RB        | Ethyl acetate | IR, UV, MS, CD, NMR | PTP 1B inhibitory activity | Strong activity [142] |         |
| Erythribyssin J (72)            | Isoflavanone   | RB        | Ethyl acetate | IR, UV, MS, CD, NMR | PTP 1B inhibitory activity | Strong activity [142] |         |
| 5-Deoxyabyssinin II (73)        | Flavanone      | RB        | Ethyl acetate | IR, UV, MS, CD, NMR | PTP 1B inhibitory activity | Strong activity [142] |         |
| 7-Demethylrobustigenin (74)     | Isoflavone     | Rt        | Chloroform : methanol (1 : 1) | UV, NMR, EI-MS, HMBC | Antimicrobial and antioxidant activities | Weak activity [134] |         |
| Erythribyssin K (75)            | Flavanone      | RB        | Ethyl acetate | IR, UV, MS, CD, NMR | PTP 1B inhibitory activity | No activity [142] |         |
| Erythribyssin II (76)           | Pterocarpan    | Rt        | Chloroform : methanol (1 : 1), methanol | UV, NMR, HPLC | Antimicrobial (antibacterial) and radical scavenging properties | Good radical scavenging, antihemalytic and antifungal activities [134, 136] |         |
| Name of the compound identified | Chemical class | Part used | Solvent used | Techniques used | Bioactivity tested | Result | Authors |
|---------------------------------|----------------|-----------|--------------|-----------------|-------------------|--------|---------|
| Liquiritigenin (77)             | Flavanone RB   | Ethyl acetate | IR, UV, MS, CD, NMR | PTP 1B inhibitory activity | No activity | [142] |
| Liquiritigenin-50-O-methyl ether (78) | Flavanone RB   | Ethyl acetate | IR, UV, MS, CD, NMR | PTP 1B inhibitory activity | No activity | [142] |
| Burttinone (79)                 | Flavone SB     | Methanol   | UV, NMR, CD, HRMS | Good activity | [138] |
| Burttinonedehydrate (80)        | Flavone SB     | Methanol   | UV, NMR, CD, HRMS | Good activity | [138] |
| Erythribyssin G (81)            | Flavanone RB   | Ethyl acetate | IR, UV, MS, CD, NMR | PTP 1B inhibitory activity | No activity | [142] |
| Erythribyssin I (82)            | Flavanone RB   | Ethyl acetate | IR, UV, MS, CD, NMR | PTP 1B inhibitory activity | No activity | [142] |
| 7-Hydroxy-4′-methoxy-3-prenylisoflavone (83) | Isoflavone SB | Methanol | UV, FTIR, TLC, NMR, HMBC | Antimicrobial and antiplasmodial activities | Moderately active | [145] |
| Octacosyl-E-ferulate (erythrinacinse A) (84) | Coumaric acid | Rt | Chloroform : methanol (1 : 1) | Antimicrobial and antioxidant activities | Weak activity | [134, 145] |
| Erythrybysin I (85)             | Pterocarpan NS | Ether, 80% MeOH | UV, NMR, EI-MS, HMBC | Antifungal activity | Good activity | [134, 136, 141] |
| Erythrybysin II (86)            | Pterocarpan Rr | Chloroform : MeOH (1 : 1), 80% MeOH | UV, NMR, EI-MS, HMBC, HPLC | Antimicrobial and antioxidant activities | Moderate activity | [134, 136, 141] |
| Genistein (87)                  | Isoflavone Rt, Tw | Chloroform : methanol (1 : 1) | UV, NMR, EI-MS, HMBC, HPLC | Antimicrobial and antioxidant activities | Weak activity | [134] |
| Neobavaisoflavone (88)          | Flavanone Rt   | Chloroform : methanol (1 : 1) | UV, NMR, EI-MS, HMBC | Antimicrobial and antioxidant activities | Weak activity | [134] |
| Semilicoisoflavone B (89)       | Isoflavone Rt   | Chloroform : methanol (1 : 1) | UV, NMR, EI-MS, HMBC | Antimicrobial and antioxidant activities | Weak activity | [134] |
| Sigmoidin A (90)                | Flavanone SB   | Methanol | UV, HPLC, HREI-MS, HMQC, HMBC, NOESY NMR | Antilipase activity | Exhibited antilipase activity | [82, 146] |
| Sigmoidin B (91)                | Flavanone Rt   | Chloroform : methanol (1 : 1) | UV, NMR, HREI-MS, HMBC, NOESY | Antimicrobial and antioxidant activities | Good activities | [82, 134] |
| Sigmoidin B 4′-(methyl ether) (92) | Flavanone SB | Methanol | UV, HPLC, HREI-MS, HMQC, HMBC, NOESY NMR | Not tested | Not applicable | [82] |
| Name of the compound identified | Chemical class | Part used | Solvent used | Techniques used | Bioactivity tested | Result | Authors |
|---------------------------------|----------------|-----------|--------------|-----------------|-------------------|--------|---------|
| Phaseolin (93)                  | Chalcone       | NS        | Ether        | UV, NMR, HMBC, EI-MS, HPLC | Antimicrobial activity | Good activity (antiyeast and antifungal activities) | [134, 136, 141] |
| Phaseollidin (94)               | Chalcone       | Rt        | Chloroform: methanol (1:1), ether | UV, NMR, HMBC, EI-MS, HPLC | Antimicrobial activity | Weak activity | [134, 136] |
| Erythartine/11-methoxyerysodine (95) | Alkaloid      | Sd        | Chloroform: methanol (1:1) | UV, NMR, HMBC, EI-MS, HPLC | Anti-HIV-1 and cytotoxicity | Weak activity | [59] |
| Caryolane-1,9-diol (96)         | Sesquiterpene  | Rt        | Chloroform: methanol (1:1) | UV, NMR, HMBC, EI-MS, HPLC | Antimicrobial and antioxidant activities | Weak activity | [134] |
| Abyssaponin A (97)              | Triterpenoid   | SB        | Ethanol      | NMR, UV, HRESI-TOFMS, ESI-MS/MS | Anticancer activity | Strong activity | [147] |
| Abyssaponin B (98)              | Triterpenoid   | SB        | Ethanol      | NMR, UV, HRESI-TOFMS, ESI-MS/MS | Anticancer activity | Strong activity | [147] |
| Soyasapogenol B (99)            | Triterpenoid   | SB        | Ethanol      | NMR, UV, HRESI-TOFMS, ESI-MS/MS | Anticancer activity | Strong activity | [147] |
| Abyssinoside A (100)            | Flavanone      | SB        | Ethanol      | NMR, UV, HRESI-TOFMS, ESI-MS/MS | Anticancer activity | Moderate activity | [147] |
| Abyssinoside B (101)            | Flavanone      | SB        | Ethanol      | NMR, UV, HRESI-TOFMS, ESI-MS/MS | Anticancer activity | Moderate activity | [147] |
| Abyssinoside C (102)            | Flavanone      | SB        | Ethanol      | NMR, UV, HRESI-TOFMS, ESI-MS/MS | Anticancer activity | Weak activity | [147] |
| Abyssinoside D (103)            | Flavanone      | SB        | Ethanol      | NMR, UV, HRESI-TOFMS, ESI-MS/MS | Anticancer activity | Moderate activity | [147] |
| Schaftoside (104)               | Flavanone      | SB        | Ethanol      | NMR, UV, HRESI-TOFMS, ESI-MS/MS | Not tested | Not applicable | [147] |
| Isoschaftoside (105)            | Flavanone      | SB        | Ethanol      | NMR, UV, HRESI-TOFMS, ESI-MS/MS | Not tested | Not applicable | [147] |
| Vicenin-2 (106)                 | Flavanone      | SB        | Ethanol      | NMR, UV, HRESI-TOFMS, ESI-MS/MS | Not tested | Not applicable | [147] |
| Hovetrichoside C (107)          | Aurananol      | SB        | Ethanol      | Not tested | Not tested | Not applicable | [147] |
| Name of the compound identified | Chemical class | Part used | Solvent used | Techniques used | Bioactivity tested | Result | Authors |
|---------------------------------|----------------|-----------|-------------|-----------------|--------------------|--------|---------|
| Sigmoidin C (108)               | Flavanone      | Rt, SB    | Chloroform : methanol (1:1), methanol | UV, NMR, HREI-MS, HMBC, NOESY, HPLC, NMR, HRMS, UV, NMR, HREI-MS, HMBC, HPLC, NOESY, HRMS, NMR, HMBC | Antimicrobial and antioxidant activities | Weak activity | [82,134] |
| Sigmoidin F (109)               | Flavanone      | Rt, SB    | Chloroform : methanol (1:1), methanol | UV, NMR, HREI-MS, HMBC, NOESY, HPLC, NMR, HRMS, UV, NMR, HREI-MS, HMBC, HPLC, NOESY, HRMS, NMR, HMBC | Antimicrobial and antioxidant activities | Weak activity | [82, 134] |
| Quercetin (110)                 | Flavone        | RB        | Acetone     | UV, NMR, HREI-MS, HMBC, NOESY, HPLC, NMR, HRMS, UV, NMR, HREI-MS, HMBC, HPLC, NOESY, HRMS, NMR, HMBC | Radical scavenging properties | Moderately active | [133] |
| 5,4′-di-O-Methylalpinumisoflavone (111) | Isoflavone   | RB        | Acetone     | UV, NMR, HREI-MS, HMBC, NOESY, HPLC, NMR, HRMS, UV, NMR, HREI-MS, HMBC, HPLC, NOESY, HRMS, NMR, HMBC | Radical scavenging properties | Weak activity | [137] |
| Erycristagallin (112)           | Pterocarpan    | RB        | Acetone     | UV, NMR, HREI-MS, HMBC, NOESY, HPLC, NMR, HRMS, UV, NMR, HREI-MS, HMBC, HPLC, NOESY, HRMS, NMR, HMBC | Radical scavenging properties | Moderately active | [133] |
| Shinpterocarpin (113)           | Pterocarpan    | RB        | Acetone     | UV, NMR, HREI-MS, HMBC, NOESY, HPLC, NMR, HRMS, UV, NMR, HREI-MS, HMBC, HPLC, NOESY, HRMS, NMR, HMBC | Radical scavenging properties | Moderately active | [133] |
| Sandwicensin (114)              | Pterocarpan    | RT        | Chloroform : methanol (1:1) | UV, NMR, HREI-MS, HMBC, NOESY, HPLC, NMR, HRMS, UV, NMR, HREI-MS, HMBC, HPLC, NOESY, HRMS, NMR, HMBC | Antimicrobial and antioxidant activities | Weak activity | [134] |
| 3,6-Caryolanediol (115)         | Sesquiterpenes | RT        | Chloroform : methanol (1:1) | UV, NMR, HREI-MS, HMBC, NOESY, HPLC, NMR, HRMS, UV, NMR, HREI-MS, HMBC, HPLC, NOESY, HRMS, NMR, HMBC | Antimicrobial and antioxidant activities | Weak activity | [134] |
| Clovane-2,9-diol (116)          | Sesquiterpenes | RT        | Chloroform : methanol (1:1) | UV, NMR, HREI-MS, HMBC, NOESY, HPLC, NMR, HRMS, UV, NMR, HREI-MS, HMBC, HPLC, NOESY, HRMS, NMR, HMBC | Antimicrobial and antioxidant activities | Weak activity | [134] |
| 7-Hydroxy-2-[(4-methoxy-3-(3-methylbut-2-enyl) phenyl] chroman-4-one (117) | Flavanone       | RB        | Ethyl acetate | IR, UV, MS, CD, NMR | PTP 1B inhibitory activity | Strong activity | [142] |
| Sigmoidin E (118)               | Flavanone      | RT, SB    | Chloroform : methanol (1:1), methanol | UV, NMR, CD, HREI-MS, HPLC, HMBC, HPLC, NOESY, UV, CD, NMR, HRMS | Antimicrobial, antioxidative and PTP 1B inhibitory activities | Weak activity | [82, 134, 138, 139] |
| Sigmoidin G (119)               | Flavanone      | SB        | Methanol    | UV, NMR, CD, HREI-MS, HPLC, HMBC, HPLC, NOESY, UV, CD, NMR, HRMS | PTP 1B inhibitory activity | No activity | [138, 139] |
| 9-Ethyllodecyl-4-methoxybenzoate (120) | Benzoate ester | SB        | Methanol    | TLC, NMR | Antibacterial and termidal activity | Moderate antibacterial activity | [62] |
| Lupinifolin (121)               | Flavonoid      | SB        | Methanol    | TLC, NMR | Antibacterial and termidal activity | Moderate antibacterial activity | [62] |
| Kaempferol 3-O-(2-O-b-D-glucopyranosyl-6-O-a-L-rhamnopyranosyl-b-D-glucopyranoside (122 | Flavonol       | Fl        | Methanol (acidified) | NMR, DQF-COSY | Not tested | Not applicable | [148] |
trans isomers. The presence of pterocarpans has been attributed to their synthesis by members of the family Fabaceae in response to infections by microorganisms as defense molecules [157]. Eleven pterocarpans (13, 16, 23, 76, 85, 86, 93, 94, and 112–114) were isolated from the roots and root bark of *E. abyssinica* [133, 134, 136, 141].

(3) Terpenoids (Sesquiterpenes and Triterpenoids). Sesquiterpenes are terpenoids with fifteen carbons (C15) consisting of three isoprene units. They are the dominant constituents of essential oils and other pharmacologically active oxygenated hydrocarbons occurring in higher plants. They naturally exist as hydrocarbons or oxygenated derivatives of hydrocarbons such as carbonyl compounds, alcohols, lactones, and carboxylic acids [158]. Three sesquiterpenes, 3,6-caryolanediol (115) and clovene-2,9-diol (116) along with caryalone-1,9-di(96), were isolated from *E. abyssinica* roots [134]. On the other hand, two new triterpenoids, abyssaponin A (97) and abyssaponin B (97) along with a triterpenoid saponin, soyasapogenol B (99), were isolated from *E. abyssinica* stem bark [147].

3.5. Pharmacology of *E. abyssinica* and Isolated Compounds. In this section, we report investigations which evaluated the pharmacological potential of both extracts and isolated pure compounds from *E. abyssinica*. Indeed, phytochemicals in this species possess antibacterial, antifungal, antiviral, anticancer, antioxidant, anti-inflammatory, antymycobacterial, anti-HIV/AIDS, antiplasmodial, antihelmintic, antiobesity, anti-ticancer, antioxidant, anti-inflammatory, antimycobacterial, anti-HIV/AIDS, antiplasmodial, antihelminthic, antiobesity, antipyrretic, anti diabetic, antianemic, and hepatoprotective bioactivities (Tables 4 and 5).

3.5.1. Anti-Inflammatory Activity. The aqueous root bark of *E. abyssinica* at doses less than 100 mg/kg showed considerable *in vivo* anti-inflammatory activity against *Trypanosoma brucei*-induced inflammation in mice [50]. The extract-treated group had a lower number of astrocyte reactivity and reduced perivascular cuffing than the nontreated mice. It was suggested that the extracts reduced the infiltration of the inflammatory cells into the cerebrum of the brain. The anti-inflammatory activity was attributed to the alkaloids and flavonoids present in the extracts although the pure compounds responsible were not identified [50]. Interestingly, other crude extracts and pure compounds isolated from members of the genus *Erythrina* have been validated to possess good anti-inflammatory activities via different mechanisms. For example, the ethyl acetate and ethanol extracts of *E. latissimi, E. caffea*, and *E. lysisemon* showed good anti-inflammatory activity through reduction in the synthesis of prostaglandins as a result of inhibition of cyclooxygenase activity [168]. Erycristagallin isolated from *E. mildbraedii* inhibited leukotriene synthesis via the 5-lipoxygenase pathway, thereby demonstrating *in vitro* anti-inflammatory activity (IC$_{50}$ = 23.4 μM) in polymorphonuclear leukocytes [169]. Three flavonoids (abysssonine V, erycristagallin, and 4’-hydroxy-6,3’-5’triprenylisoflavonone) isolated from the methanolic stem bark extract *E. variegate* had strong phospholipase A2 (PLA2) inhibitory activity with IC$_{50}$ values of 6, 3, and 10 μM, respectively [170]. This implied that these compounds can significantly reduce the synthesis of arachidonic acid and consequently diminish the synthesis of prostaglandins and leukotrienes. Two prenylated flavanones (sigmoidin A and sigmoidin B) isolated from *E. sigmoidea* were reported to selectively inhibit 5-lipoxygenase but had no effect on cyclooxygenase-1 activity. Sigmoidin A had a dose-response inhibitory potency (IC$_{50}$ = 31 mM). In the PLA2-induced mouse paw oedema assay, only the sigmoidin B inhibited oedema formation with a percentage inhibition of 59% compared to cyproheptadine (positive control) which had 74% after 60 minutes. In the TPA test, both compounds reduced the induced oedema by 89% and 83%, respectively. It was suggested that the compounds had different mechanisms of action depending on whether one or two prenyl groups were present in ring B of the flavonoid [83]. Since these same compounds have been isolated from *E. abyssinica*, it is highly probable that the reported anti-inflammatory activity of this plant is due to one or a combination of these mechanisms.

3.5.2. Antioxidant Activity. The *in vitro* 2, 2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay has been widely used to evaluate the antioxidant activity of various phytochemicals and extracts. The ethanolic extract of *E. abyssinica* (10–320 μg/mL) showed dose-dependent DPPH radical scavenging that was comparable to that of ascorbic acid (a known antioxidant) [159]. Abyssinone VII, sigmoidin B, eryvarin L, and 3-methylbutene isolated from the stem bark and root wood of *E. abyssinica* showed considerable DPPH radical scavenging potency (IC$_{50}$ = 12–52 μg/mL) although the standard antioxidants (ascorbic acid, gallic acid, and quercetin) had superior activity (IC$_{50}$ = 4–18 μg/mL) [134]. The acetone crude extract of the root bark of *E. abyssinica* (IC$_{50}$ = 7.7 μg/mL) and two isolated pterocarpenes, erycristagallin (IC$_{50}$ = 8.2 μg/mL) and 3-hydroxy-9-methoxy-10-(3,3-dimethylallyl) pterocarpe (IC$_{50}$ = 10.8 μg/mL), showed DPPH radical scavenging activity in a dose-dependent manner similar to that of quercetin (IC$_{50}$ = 5.4 μg/mL) [133]. The radical scavenging activity of these compounds is due to their free phenolic groups which can donate electrons to the radicals [171]. For flavonoids, the O-dihydrxyl structure in the B ring, the 2,3-double bond in conjunction with the 4-oxo function in the C ring, and the 3- and 5-hydroxyl groups with hydrogen bonding to the keto group are responsible for the antioxidant activity. In pterocarps, the 3,3-dimethylallyl groups enhance the radical scavenging activities and also increase the lipophilicity of these compounds making them better antioxidants than polar flavonoids [133].

3.5.3. Anticancer Activity. The chloroform, methanol, and ethyl acetate extracts showed cytotoxic activity against different tumor cells (cervical, liver, laryngeal, colon, and breast) and strongly inhibited protein tyrosine phosphatase (PTP1B) activity with IC$_{50}$ ranging between 1 and 100 μg/mL. Using the dimethylthiazol-2,5-diphenyl-tetrazolium
Table 5: Pharmacological profile of different parts of *E. abyssinica*.

| Activity          | Model used | Plant part                  | Extract/compound | Bioassay                      | Results                                                                                                                                                                                                 | Author(s) |
|-------------------|------------|-----------------------------|------------------|-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Antioxidant       | *In vitro*| Ethanol, methanol           | Leaves, root bark| DPPH radical scavenging assay| Extract showed dose-dependent DPPH radical scavenging activity that was comparable to that of ascorbic acid at all doses (10–320 μg/mL). After 1 h, the DPPH radical scavenging activity was as follows: abyssinone VII: IC₅₀ = 25 μg/mL, sigmoidin B: IC₅₀ = 18.5 μg/mL, eryvarin L: IC₅₀ = 29 μg/mL, and 3-methylbutein: IC₅₀ = 37 μg/mL, ascorbic acid: IC₅₀ = 18 μg/mL, gallic acid: IC₅₀ = 4 μg/mL, and quercetin: IC₅₀ = 7 μg/mL. After 30 minutes, the DPPH radical scavenging activity was as follows: crude extract: IC₅₀ = 7.7 μM, abyssinone IV: 32.4 μM, abyssinone V: 30.1 μM, abyssinin III: 21.7 μM, erycristagallin: IC₅₀ = 8.2 μM, 3-hydroxy-9-methoxy-10-(3,3-dimethylallyl) pterocarpene: IC₅₀ = 10.8 μM, and quercetin: IC₅₀ = 5.4 μM. The aqueous extract-treated group (50 mg/kg) had lower astrocyte reactivity (34,545 astrocytes/mm³) than the untreated group (69,886 astrocytes/mm³). Also, they had a reduced degree of neuroinflammation (1.2) compared to the untreated group (2.8). The extract was thought to reduce the infiltration of inflammatory cells into the cerebrum. The methanol extract did not have a significant effect on the modulation of neuroinflammation (38% inhibition factor against hyperglycemia at a dose of 500 mg/kg (6 mg/kg glibenclamide = 49.6%). | [127,159] |
|                   |            | Abyssinone VII              |                  |                               | [134]                                                                                                                                                                                                    |           |
|                   |            | Sigmoidin B                 |                  |                               | [133]                                                                                                                                                                                                    |           |
|                   |            | Eryvarin L                  |                  |                               | [50]                                                                                                                                                                                                     |           |
|                   |            | 3-Methylbutein              |                  |                               | [114]                                                                                                                                                                                                    |           |
| Anti-inflammatory | *In vivo*  | Root bark                   | Chronic trypanosomiasis-induced neuroinflammation mouse model |                               |                                                                                                                                                                                                           |           |
| Antihyperglycemic | *In vivo*  | Root bark                   | Water            | Oral glucose tolerance assay using male guinea pigs (*Cavia porcellus*) |                                                                                                                                                                                                           | [114]     |
| Activity       | Model used | Plant part | Extract/compound | Bioassay | Results                                                                                                                                          | Author(s) |
|----------------|------------|------------|-------------------|----------|--------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Antihyperglycemic | *In vivo*  | Leaf       | Ethanol           | Oral glucose tolerance assay using male Wistar albino rats | After 4 hours of hyperglycemia induction, the extract significantly and dose dependently reduced the mean blood glucose; 100 mg/kg = 25%, 200 mg/kg = 46.4%, 400 mg/kg = 60.7%, and 5 mg/kg glibenclamide = 35.7% Compounds exhibited PTP1B inhibitory activity with IC₅₀ values ranging from 4.2 to 19.3 μM and strong cytotoxic activity with IC₅₀ values from 5.6 to 28.0 μM | [159]    |
| Anticancer     | *In vitro* | Stem bark  | Ethanol           | MTT and protein tyrosine phosphatase (PTP1B) inhibitory assay | After 72 hours of exposure; MCF7: IC₅₀ = 19.4 μM, MCF/AMR: IC₅₀ = 12.0 μM, MCF/ADR: IC₅₀ = 16.1 μM, MDA-MB-231: IC₅₀ = 28.0 μM, and PTB1B: IC₅₀ = < 30 μM. The crude alkaloidal fraction showed cytotoxic activity against the tumor cells with IC₅₀ values of 13.8, 10.1, 8.16, 13.9, 11.4, and 12.2 μg/mL against HeLa, Hep-G2, HEP-2, HCT116, MCF-7, and HFB4 cells, respectively. After 72 hours of exposure, the IC₅₀ of isolated compounds on Hep-G2 and HEP-2 cells were as follows, respectively: erythraline: IC₅₀ = 21.60 and 15.8 μg/mL, erysodine: IC₅₀ = 19.90 and 11.8 μg/mL, Erysotrine: IC₅₀ = 21.60 and 15.8 μg/mL, 8-oxoerythraline: IC₅₀ = 18.50 and 3.89 μg/mL, 11-methoxyerysodine: IC₅₀ = 11.50 and 11.4 μg/mL | [160]    |
| Anticancer     | *In vitro* | Seeds      | Chloroform        | Sulforhodamine B assay using HeLa, Hep-G2, HEP-2, HCT116, MCF-7, and HFB4 cells | After 72 hours of exposure, the IC₅₀ of isolated compounds on Hep-G2 and HEP-2 cells were as follows, respectively: erythraline: IC₅₀ = 21.60 and 15.8 μg/mL, erysodine: IC₅₀ = 19.90 and 11.8 μg/mL, Erysotrine: IC₅₀ = 21.60 and 15.8 μg/mL, 8-oxoerythraline: IC₅₀ = 18.50 and 3.89 μg/mL, 11-methoxyerysodine: IC₅₀ = 11.50 and 11.4 μg/mL | [59]     |
| Activity                      | Model used | Plant part | Extract/compound | Bioassay                                | Results                                                                                                                                                                                                 | Author(s) |
|-------------------------------|------------|------------|------------------|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Antianaemic                   | *In vivo*  | Stem bark  | Water extract    | Phenyl hydrazine                        | Improved haematocrit activity in a dose-dependent manner. Extracts increased the red blood cell differentials in anaemic rats at increasing doses of 50, 100, and 350 mg/kg IC50 = 4.5 and 62.5 μM for pancreatic lipase and alpha glucosidase inhibition, respectively (orlistat = 0.3 μM, acarbose = 190.6 μM) At a dose of 200 mg/kg, the extract reduced the average number of hot flushes (171 in treated vs. 264 in the untreated group). The treated group also had shorter durations of hot flushes (683 minutes) compared to the untreated (1935 minutes) The extract had significant effects on fasting blood glucose as well as hepatic indices including liver weights, hepatic triglycerides, liver weight-body weight ratio, serum AST, serum ALT levels, serum triglycerides, serum total cholesterol, and serum LDL-cholesterol; however, the extracts showed no significant effects on HDL-cholesterol. At high doses (400 mg/kg), the extract protected the liver against inflammation, steatosis, and hepatic ballooning 82.1 and 88.7% wound area healed after 15 days for the stem bark and leaf extract, respectively, at a dose of 10% w/w The mean skin protein was 32.5 and 35.5% for the stem bark and leaf, respectively (oxytetracycline = 40.5%). Although the leaf extract had better healing properties than the bark, there was no significant difference between both extracts and the negative control. | [128]     |
| Antiobesity                   | *In vitro* | Stem bark  | Sigmoidin A      | Pancreatic lipase and alpha-glucosidase inhibition assay |                                                                                                                                                                                                       | [146]     |
| Antipyretic and estrogenomimetic | *In vivo* | Stem bark  | Methanol         | Smart button data loggers using ovariectomized rats using | Nonalcoholic fatty liver disease model using rats to evaluate the fasting blood glucose, insulin tolerance, hepatic triglycerides, serum biochemistry, and liver histology.                                                                 | [161]     |
| Hepatoprotective              | *In vivo*  | Stem bark  | Water            |                                                                                                  |                                                                                                                                                                                                       | [162]     |
| Wound healing                 | *In vivo*  | Leaf and stem bark | Methanol | Wound incision assay                                                                 |                                                                                                                                                                                                       | [94]      |
| Activity       | Model used | Plant part       | Extract/compound | Bioassay                                                                 | Results                                                                 | Author(s) |
|---------------|------------|------------------|------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------|-----------|
| Antiplasmodial | *In vivo*  | Stem and root bark | Acetone           | Four-day ANKA suppressive bioassay using *P. berghei*                     | % chemosuppression: root (49.7%), stem (44.2%), and chloroquine (97.3%) | [163]     |
|               |            |                  | n-Hexane         | Nonradioactive antimalarial 3H hypoxanthine inhibition assay               | After 24 hours, n-hexane extract: IC$_{50}$ = 0.0 μg/mL, methanol extract: | [145]     |
|               |            |                  | Dichloromethane (DCM) |                                                                            | IC$_{50}$ = 190.1 μg/mL, methanol extract: IC$_{50}$ = 348.2 μg/mL,          |           |
|               |            |                  |                  |                                                                            | mefloquine: IC$_{50}$ = 19.2 μg/mL.                                        |           |
| Antiplasmodial | *In vitro* | Leaves           | Methanol          | Four-day ANKA suppressive bioassay using *P. falciparum*                   | IC$_{50}$ = 7.9 μg/mL, W2: IC$_{50}$ = 5.3 μg/mL, flavonoids: IC$_{50}$     | [49]      |
|               |            |                  |                  |                                                                            | ranged from 10 to 16 μM, flavonones: IC$_{50}$ ranged from 4.9 to 13.6 μM, |           |
|               |            |                  |                  |                                                                            | isoflavonoids: IC$_{50}$ ranged from 18.2 to 24.9 μM, chloroquine: IC$_{50}$ |           |
|               |            |                  |                  |                                                                            | ranged from 0.09 to 0.08 μM, and quinine: IC$_{50}$ ranged from 0.04 to 0.21 μM |           |
|               |            |                  |                  |                                                                            | At 50 mg/kg of the extract, % chemosuppression: root bark (77%), stem bark (32%), and 10 mg/kg chloroquine (6%). |           |
| Antiplasmodial | *In vitro* | Stem             | Isolated compounds (chalcones, flavonones, isoflavonoids) | Four-day ANKA suppressive bioassay using *P. falciparum* and *P. berghei* | Survival time in extract-treated and chloroquine-treated groups was 2- to 3-fold higher than the untreated. | [28, 164] |
| Antiviral      | *In vitro* | Seeds and stem   | Chloroform, ethanol | MTT assay using HIV-1-infected MT-4 cells                                  | For *P. falciparum*, IC$_{50}$ of 7.81 μg/mL (K1 strain) Stem alkaloidal fraction: IC$_{50}$ = 53 μM, efavirenz: IC$_{50}$ = 45 μM | [59, 112] |
| Antimycobacterial | *In vitro* | Stem bark       | Methanol          | Microdilution assay against *Mycobacterium tuberculosis*, *Mycobacterium kansasii*, *Mycobacterium fortuitum*, and *Mycobacterium smegmatis* | Stem had antiviral activity (reduction factors of the viral titer of 10$^3$) against polio, Semliki forest, and herpes viruses At a dose of 2 mg/mL, the extract completely inhibited the growth of all Mycobacterial strains (0 GU). However, at 1 mg/ mL, there was significant growth of *Mycobacterium tuberculosis* (19741 GU), *Mycobacterium kansasii* (724 GU), *Mycobacterium fortuitum* (174 GU), and *Mycobacterium smegmatis* (4915 GU) | [165]     |
| Activity            | Model used | Plant part | Extract/compound | Bioassay                          | Results                                                                                       | Author(s) |
|---------------------|------------|------------|------------------|-----------------------------------|-----------------------------------------------------------------------------------------------|-----------|
| Antimycobacterial   | *In vitro* | Root bark  | Methanol         | Microdilution assay against pan-sensitive strain (H37Rv), rifampicin-resistant strain (TMC-331), *Mycobacterium avium* | MIC of extract against H37Rv: 0.39 mg/mL, TMC-331: 2.35 mg/mL. The MICs of isoniazid were 0.25 μg/mL and 9.38 μg/mL for H37Rv and TMC-331, respectively | [126]     |
| Antimycobacterial   | *In vitro* | Stem bark  | Ethanol          | Microdilution assay against *M. tuberculosis* | Percentage inhibition of colony formation of different combinations: 0.06 μg/mL ethanol extract with 0.01 μg/mL rifampicin and isoniazid = 99.2%, 0.06 μg/mL methanol extract with 0.01 μg/mL rifampicin and isoniazid = 99% and 0.01 μg/mL rifampicin and isoniazid = 86.2% | [166]     |
| Antihelmintic       | *In vitro* | Leaves     | Ethanol          | Worm motility assessment assay on *Ascaridia galli* | After 24 hours of exposure, at 50 mg/kg of extracts, average number of worms immobilized out of 10: leaf = 9.46, stem = 7.17, root = 7.92, piperazine = 10. At 5% concentration of extracts, average number of worms immobilized out of 10 at different times: 12 h = 5, 24 h = 6, 36 h = 9, 48 h = 10 | [124]     |
| Antihelmintic       | *In vitro* | Leaves     | Ethanol          | Worm motility assessment assay on *Ascaridia galli* |                                                                                               | [120]     |
Table 5: Continued.

| Activity                     | Model used | Plant part                            | Extract/compound          | Bioassay                                                                 | Results                                                                 | Author(s) |
|------------------------------|------------|---------------------------------------|---------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-----------|
| Antibacterial                | *In vitro* | Stem and root barks, whole plant, leaves | Ethanol, methanol, chloroform, water | Microbroth dilution assay against *S. aureus* *E. coli,* *E. coli,* *S. typhi,* *B. cereus,* and *P. aeruginosa.* |-Ethanolic extracts inactive against *E. coli,* *S. typhi,* and *P. aeruginosa.* Extracts exhibited different antibacterial activities against *S. aureus* depending on the part of the plant and also the location from where they were harvested. In Mbarara, the root extract was more active (MIC 31.3 mg/mL) than the stem extract (MIC = 3.5 mg/mL). On the other hand, the root extract of Bushenyi was more active (31.3 mg/mL) than that of Ntungamo (4.7 mg/mL). Methanolic extract showed better antibacterial activity (6.0 mm inhibition diameter, MIC = 0.23 mg/mL) against *S. aureus* than the positive reference controls: ampicillin (4.0 mm) and amoxicillin (5.0 mm). Chloroform extract of the whole plant had bioactivity against *S. aureus,* with 7.45 mm inhibition zone diameter. Methanolic extract of root bark showed bioactivity against *S. aureus,* *B. cereus,* and *P. aeruginosa* with MIC and MBC of 3.125, 125.00, and 62.50, 100.00, and 250.00 mg/mL, respectively. Aqueous extract of root bark showed bioactivity against *S. aureus,* *B. cereus,* *E. coli,* and *P. aeruginosa* with MIC and MBC of 3.125, 12.50, 250.00, and 125.00, and 3.125, 25.00, 250.00 and 250.00 mg/mL, respectively. Leaf powder exhibited potential antidiarrheal activity in mice. | [19, 26, 91, 123, 127] |
Table 5: Continued.

| Activity                          | Model used | Plant part          | Extract/compound | Bioassay                                      | Results                                                                 | Author(s) |
|----------------------------------|------------|---------------------|------------------|-----------------------------------------------|-------------------------------------------------------------------------|-----------|
| **Antibacterial**                | *In vitro* | Stem and root bark | Methanol         | Microbroth dilution assay against *Bacillus*    | The extracts were not active on all the bacterial strains              | [100]     |
|                                  |            |                     |                  | *cereus*, *E. coli*, *Micrococcus luteus*,     | *E. coli* and *P. aeruginosa*: MIC values of all compounds were greater |           |
|                                  |            |                     |                  | and *P. aeruginosa*                           | than 100 μg/mL; *S. aureus*: with exception of abyssinone II and VI,    |           |
|                                  |            |                     |                  | all the other compounds had MIC values below  | all the other compounds had MIC values below 100 μg/mL.                 |           |
|                                  |            |                     |                  | 100 μg/mL.                                   | *Bacillus subtilis*: with exception of abyssinones II and VI, all the |           |
|                                  |            |                     |                  |                                               | other compounds had MIC values above 100 μg/mL.                       |           |
|                                  |            |                     |                  |                                               | *S. cerevisiae* and *C. utilis*: with exception of erythrabysin I and  | [60, 141] |
|                                  |            |                     |                  |                                               | phaseolin, all the other compounds had MIC values above 100 μg/mL.    |           |
|                                  |            |                     |                  |                                               | *M. mucido*: with exception of erythrabysin I, abyssinones I and II,    |           |
|                                  |            |                     |                  |                                               | Phaseolin, all the other compounds had MIC values greater than 100    |           |
|                                  |            |                     |                  |                                               | μg/mL. Extract had effective MICs at 25% (w/v) and 12.5% (w/v) with      |           |
|                                  |            |                     |                  |                                               | moderate fungal growth observed at 6.25% (w/v) against C. neoformans   |           |
|                                  |            |                     |                  |                                               | and C. albicans                                                        |           |
bromide (MTT) assay, the abyssinones A–D and abyssaponins (A and B) isolated from *E. abyssinica* stem bark exhibited considerable cytotoxicity against MCF-7 and MDA-MB-231 breast adenocarcinoma cell lines with IC50 ranging between 12.9 and 74 μM as compared to resveratrol (IC50 13.9–19.3 μM)[147]. However, related phytochemicals isolated from *E. suberosa* showed to induce apoptosis through the inhibition of NF-κB factor and via an increase in cytosolic cytochrome C that stimulates caspases 9 and 3 which further activates intrinsic apoptosis pathway [172].

3.5.4. Antidiabetic and Antiobesity Activity. The aqueous extract of this plant showed significant antihyperglycemic activity at a dose of 500 mg/kg in rats using the oral glucose tolerance test (OGTT) with a hyperglycemia inhibition factor of 38.5% as compared to glibenclamide (49.6%). It was suggested that probably the inhibition of the SLGT-1 and GLUT-2 transporters along with α-glucosidase were the possible mechanisms for the antidiabetic activity [114]. In an acute OGTT, the ethanolic extract of *E. abyssinica* significantly decreased blood glucose levels in both normal and streptozotocin- (STZ-) induced diabetic rats in a dose-dependent manner (100, 200, and 400 mg/kg) when compared with negative (normal saline) and positive control (glibenclamide) [159]. In a subchronic antidiabetic

| Activity                          | Model used | Plant part | Extract/compound | Bioassay                          | Results                                                                 | Author(s) |
|-----------------------------------|------------|------------|------------------|-----------------------------------|------------------------------------------------------------------------|-----------|
| Antibacterial and antifungal      | *In vitro*| Stem bark  | Hexane, dichloromethane, methanol | Microbroth dilution assay against *E. coli*, *S. aureus*, *P. aeruginosa*, *K. pneumoniae*, *Microsporum gypseum*, *Trichophyton mentagrophytes*, *C. albicans*, *Cryptococcus neoformans* | Extracts not active on *E. coli*, weak activity against *P. aeruginosa* and *K. pneumoniae* (MIC greater than 50 mg/mL). The methanol extract more active on MRSA (MIC = 6.25 mg/mL) and DCM on *S. aureus* (MIC = 25.0 mg/mL). Hexane extracts were the least active on all strains. All extracts had good activity against *M. gypseum* (MIC less than 12.5 mg/mL) but weak activity against *C. albicans* and *C. neoformans* (MIC greater than 100 mg/mL). The hexane extract was active on *T. mentagrophytes* (MIC = 25.0 mg/mL). Lupinifolin and 9-ethyldecyl 2-hydroxy-4-methoxybenzoate from methanolic extract had zone of inhibition of 9.0 mm each against *B. subtilis* and *E. coli*, respectively. The compounds and crude extract inhibited *Fusarium* spp., *Trichophyton* spp., and *Penicillium* spp. with inhibition zones of 9.0–18.0 mm. | [62, 167]  |

MIC: minimum inhibitory concentration; IC50: inhibitory concentration; GU: growth units.
test, daily oral administration of the same doses of extract for six weeks significantly lowered blood glucose levels in STZ-induced diabetic rats in a dose-dependent manner when compared with the diabetic control group. In this study, glibenclamide (5 mg/kg) significantly lowered blood glucose in nondiabetic rats only but not in diabetic rats [159].

Benzofurans, coumestans, and flavanones isolated from the stem bark of *E. abyssinica* had marked stimulation of the AMP-activated protein kinase (AMPK) activity with varying potencies at 10 μM concentrations with coumestans and benzofurans showing the highest potency. The prenyl groups in coumestans and benzofurans were suggested to be responsible for the enhanced stimulatory activity while their substitution with a methoxy group in the B ring could be responsible for the decreased activation of the AMPK. Activated AMPK plays a critical role in glucose and lipid metabolism such as enhancing insulin sensitivity, stimulating glucose uptake in the muscles, suppressing glycogenesis in the liver, increased oxidation of fatty acids oxidation, and diminished fatty acid synthesis. All these mechanisms are responsible for the antidiabetic activity of the isolated phytochemicals [144]. Further, prenylated flavanones from the stem bark of *E. abyssinica* inhibited protein tyrosine phosphate 1B (PTP1B) activity in an *in vitro* assay with IC50 values ranging from 15.2 to 19.6 μM compared to RK-682 (positive control, IC50 = 4.7 μM). Since PTP1B regulates the insulin and leptin signaling pathways, its inhibition has been reported to result in hypoglycemic effect, and hence, its inhibitory compounds have a great potential in acting as antidiabetic and antiobesity agents [135, 142, 160]. Sigmoidin A, a flavanone isolated from the stem bark of this plant at 10 μM inhibited the growth of *P. falciparum* (D6) with IC50 of 190.6 μM, a standard antidiabetic agent [146].

3.5.5. Antiparasitic Activity. The antiplasmodial activity of *E. abyssinica* has been evaluated using the nonradioactive antimalarial activity (*in vitro*) and four-day *Plasmodium berghei* ANKA suppressive (*in vivo*) bioassays [163]. The ethyl acetate extracts had strong *in vitro* antimalarial activity against chloroquine-resistant and chloroquine-sensitive *Plasmodium* strains with IC50 values of 5.3 and 7.9 μg/mL, respectively [49, 163]. Subsequently, isolated chalcones, flavanones, and isoflavonoids had promising antimalarial activity against chloroquine-sensitive and chloroquine-resistant *P. falciparum* strains with IC50 ranging from 4.9 to 24.9 μM although chloroquine still had superior activity [49].

Another earlier *in vitro* study by Kebenei et al. [143] assessed the possible use of artemisinin in combination with a potential antimalarial drug from ethyl acetate extract of *E. abyssinica* stem bark reported that abyssinone V isolated from the extract was effective against chloroquine-sensitive (D6) *P. falciparum* parasites with IC50 value of 3.19 μg/mL. The interaction of artemisinin and abyssinone V analyzed using combination ratios of 10:90 to 90:10, respectively, against *P. falciparum* led to the identification of an antimalarial combination therapy of artemisinin and abyssinone V with sum of fraction inhibiting concentration (FIC) of 0.79 at a ratio of 2:3, respectively [143].

In an *in vivo* study, the root extracts of this plant suppressed *P. berghei* infection by 77%, 71%, and 48% in mice treated at 50, 25, and 12.5 mg/kg, respectively. It was also found out that the mice treated with a higher dose (50 mg/kg) had a significantly longer survival time than those treated with lower doses and even chloroquine [164]. The crude leaf extracts of *E. abyssinica* had weak activity against *P. falciparum* chloroquine-sensitive Sierra Leone I (D6) and multidrug-resistant Indochina I (W2) strains with IC50 ranging from 165 to 468 μg/mL [145]. Conversely, erythrinamate A and 7-hydroxy-4′-methoxy-3-prenylisoflavone isolated from *E. abyssinica* methanolic leaf extract had moderate antimalarial activity against W2 and D6 with IC50 between 120 and 150 μg/mL [145]. Isolated compounds had a much higher antimalarial activity than the crude extract. Isolation removes matrix interference and increases the concentration of the active ingredient at the drug target [173]. In another study, the ethyl acetate extract of this plant at 10 μg/mL inhibited the growth of *P. falciparum* by 83.6% as compared to chloroquine (98.1%) [73]. This antiplasmodial activity was also confirmed in *E. burtii*, a related species. The acetone root bark extract of *E. burtii* had good *in vitro* antimalarial activity against the chloroquine-resistant and chloroquine-sensitive *P. falciparum* strains with IC50 of 1.73 and 0.97 μg/mL, respectively [163]. The methanolic leaf extract of *E. abyssinica* also exhibited moderate mosquitocidal and larvicidal activities with 65.3% and 65.1% mortality and corresponding IC50 values of 231.90 and 218.90 mg/mL, respectively. However, the activities were lower compared to that of the standard drug temephos (99.90%) [49, 145].

The antihelmintic activity of *E. abyssinica* has been validated using the worm motility assessment assay on *Ascaridia galli*. The ethanolic leaf extract of this plant at increasing doses up to 50 mg/mL had good antihelmintic activity against *A. galli* comparable to that of piperazine [124]. At 50 mg/mL, the extract immobilized 95% of the worms as compared to 100% of the standard drug. In another study, 5% concentration of the extract killed all the worms after 48 hours [120]. Although the active phytochemicals were not identified, it was suggested that the antihelmintic activity of this plant could be due to tannins and alkaloids present in the crude extracts. This is because tannins are polyphenolic compounds like some synthetic antihelmintic drugs such as oxyxozanide and niclosamide. Therefore, the tannins could in a similar way interfere with energy release in the worms through uncoupled oxidative phosphorylation. But also, the tannins could bind to free proteins in the gastrointestinal tract or glycoprotein on the cuticle of the helminth, thereby impairing food absorption,
motility, and reproduction. On the other hand, alkaloids being able to stimulate excitatory cells could cause neurological dysfunction that result in paralysis and consequent death of the parasites [124].

3.5.6. Antibacterial and Antifungal Activities. The antibacterial and antifungal activities of the crude extracts and isolated compounds of *E. abyssinica* have been widely evaluated using the microbroth dilution assay against various pathogens. The bacteria tested against included *Escherichia coli*, *Staphylococcus aureus*, *Bacillus subtilis*, methicillin-resistant *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Salmonella typhi*, and *Bacillus cereus* while the fungi were *Micrococcus luteus*, *Candida utilis*, *Candida albicans*, *Mucor mucedo*, *Saccharomyces cerevisiae*, *Penicillium crustosum*, *Microsporum gypseum*, *Trichophyton mentagrophytes*, and *Cryptococcus neoformans*. The hexane, dichloromethane, ethyl acetate, methanol, and ethanol extracts of this plant showed antibacterial and antifungal activities with minimum inhibitory concentrations (MICs) between 3 and 10,000 μg/mL against different pathogens. Generally, the extracts had strong activity against Gram-positive bacteria and moderate to weak activity against Gram-negative bacteria [100, 123, 141, 145, 167, 174, 175]. It was suggested that this could be due to the unique cell wall of Gram-negative bacteria which consists of an additional lipopolysaccharide layer and periplasmic space that make it difficult for antibiotics to penetrate into them. The wide variation in the MIC values could be due to the difference in the resistance profiles of the tested microorganisms with those strains that are more resistant having higher values of MIC compared to the sensitive strains. Although standard drugs had superior activity, isolated pure compounds had higher activity (slightly lower MIC values) than the crude extracts. Flavonoids from the stem bark had MIC ranging between 0.3 and 10 μg/mL against *B. subtilis*, *S. aureus*, *E. coli*, and *S. cerevisiae* as compared to the antibacterial chloramphenicol (MIC = 0.001–0.5 μg/mL) and antifungal miconazole (MIC = 0.005 μg/mL) [134]. Two pterocarpans and eight flavonoids isolated from the root bark had significant activity against *S. aureus* and *B. subtilis* with MIC ranging between 6.25 and 50 μg/mL. But moderate activity against many Gram-negative bacterial and fungal strains with MIC greater than 100 μg/mL [141], Phasoelin and erythrobysin I showed significant antifungal activity (MIC = 6–50 μg/mL) against *S. cerevisiae*, *C. utilis*, *R. chinensis*, and *M. mucedo* [136]. In a recent study, Schultz et al. [176] reported that ethyl acetate and ethanol extracts of *E. abyssinica* bark did inhibit *Enterococcus faecium* EU-44 (IC50 = 64 μg/mL and MIC > 256 μg/mL), *Staphylococcus aureus* UAMS-1 (IC50 = 32 μg/mL and MIC 64 μg/mL), *Acinetobacter baumanii* CDC-0033 (IC50 => 256 μg/mL and MIC > 256 μg/mL) but had no activity against *Klebsiella pneumoniae* CDC-004, *Pseudomonas aeruginosa* AH-71, and *Enterobacter cloacae* CDC-0032. Further, the extracts did not exhibit quorum sensing above 40% at 16 μg/mL in a quorum-sensing inhibition plant extract library screen on *S. aureus* accessory gene regulator I reporter strain [176]. No study reported the mechanism of action of either the extracts or isolated compounds. Therefore, it remains to be determined whether the phytochemicals are microbiostatic or microbicidal.

3.5.7. Antimycobacterial Activity. The crude methanolic root extract of *E. abyssinica* showed considerable antimycobacterial activity on the rifampicin-resistant (TMC-331) and pan-sensitive (H37Rv) *Mycobacterium tuberculosis* strain with a MIC of 2.35 mg/mL and 0.39 mg/mL, respectively. The MICs for isoniazid were 9.38 and 0.25 μg/mL for TMC-331 and H37Rv, respectively [126]. In another study using the automated BACTEC Mycobacterial Growth Indicator Tube (MGIT) 960 TB system, the methanolic root bark of this plant inhibited the growth of four Mycobacterial strains (*M. tuberculosis*, *M. smegmatis*, *M. kansasii*, and *M. fortuitum*) at a concentration of 2 mg/mL. Isoniazid, a standard antitubercular drug had a growth inhibitory concentration of 0.5 mg/mL [177]. In a synergistic interaction study, the methanol and ethanol extracts of *E. abyssinica* (0.49 μg/mL) when combined with either rifampicin or isoniazid (0.01 μg/mL) had a complete inhibitory effect on the growth of *M. tuberculosis* (H37Rv). The standard drugs and methanol and ethanol extracts at the same tested concentration had innumerable, 125 and 10 colony-forming units [166]. It was postulated that probably the flavonoids, alkaloids, tannins, and terpenoids present in the extracts interacted with the standard drugs at the drug target levels, hence enhancing the activity of each other. The confirmed synergism could be used to explain the concomitant use of herbal medicines alongside the conventional therapies but also reaffirms the benefit of combination therapy in the management of susceptible and resistant tuberculosis. Despite the widespread use of *E. abyssinica* in the traditional management of tuberculosis, we did not find any reports on isolation and characterization of compounds from this plant against *M. tuberculosis*.

3.5.8. Antiviral Activity. The anti-HIV-1 activity of this plant was evaluated using the MTT method. The alkaloidal fraction showed cytotoxicity of HIV-1-infected MT-4 cells with an IC50 of 53 μM compared to efavirenz which had an IC50 of 45 μM. The anti-HIV activity was attributed to the isquinoline-type alkaloids present in the fraction that inhibit the HIV-1 replication through inhibition of viral entry and reverse transcription processes [59]. The other antiviral activities of this plant have not been validated. However, erysodine, erysotrine, and erythraline isolated from *E. cristagalli* but also present in *E. abyssinica* showed significant antiviral activity against tobacco mosaic virus (TMV) with IC50 of 1.48, 1.28, and 1.52 μM, respectively, using the leaf disc method. The positive control ngnanmycin had an IC50 of 0.18 μM [178]. Of great interest was the new alkaloid glycoside, erythraline-11-β-O-glucopyranoside which showed a much superior antiviral activity (IC50 = 0.59 μM) against TMV as compared with its aglycone, erythraline (IC50 = 1.52 μM).
3.5.9. Antianaemic and Hepatoprotective Activity. The haematinic activity of this plant was evaluated in mice using the phenyl hydrazine-induced anaemic mice model. At doses less than 100 mg/kg, the aqueous stem bark extract of *E. abyssinica* significantly increased the diminished levels of haemoglobin (Hb), red blood cells (RBCs), and packed cell volume (PCV) in mice at the end of four weeks following daily oral administration of the extract. On the other hand, the extract did not have a significant effect on the levels of white blood cells, mean corpuscular volume, mean corpuscular haemoglobin, and other differentials. The observed antianaemic activity was attributed to the flavonoids, alkaloids, and cardiac glycosides present in the aqueous extracts. However, isolation and characterization were not done to identify the pure compounds responsible for this activity.

The hepatoprotective effect of the extract was evaluated using the nonalcoholic fatty liver disease (NAFLD) model on rats fed on high-fat and glucose diet. The water extracts at daily oral doses of 200 and 400 mg/kg for 56 days showed significant inhibitory effects against the development of nonalcoholic fatty liver disease. The extract was hepatoprotective against steatosis, inflammation, and hepatic ballooning. The extracts also significantly altered other hepatic-related biochemical indices as compared to standard drug pioglitazone [162]. This hepatoprotective activity was attributed to the coumestans, benzofurans, and pterocarpans present in the water extracts that regulate the activity of AMP kinases and protein tyrosine phosphatase 1B.

3.5.10. Antipyretic and Estrogenic Activity. The estrogenic activity of this plant was studied using the smart button data logger model in ovariectomized rats. The methanol extract (200 mg/kg) and estrogen (1 mg/kg) reduced the number and frequency of hot flushes [171] as compared to those ovariectomized rats that did not receive the extract (264). Also, the rats treated with extract and estrogen had significantly reduced durations (683 and 869 minutes, respectively) of hot flushes than the untreated rats (1935 minutes). Thus, the methanol extract seemed to offer protection against small temperature rises which trigger hot flashes in the ovariectomized untreated rats. Although the real chemicals in the extract responsible for the antipyretic activity were not identified, it was postulated that the chemicals mimic estrogen by increasing the sweating threshold and thermoneutral zone size [161]. In a related study, the estrogenic activity of the erythroidines isolated from *E. poeppigiana* was evaluated using various estrogen receptor- (ER-) dependent test systems. These included the receptor binding affinity and cell culture-based ER-dependent reporter gene assays. It was found out that both α-erythroidine and β-erythroidine showed significant binding affinity values for ERα of 0.015 % and 0.005%, respectively, whereas only β-erythroidine bound to ERβ (0.006 %). In reporter gene assays, both erythroidines showed a significant estrogenic stimulation of ER-dependent reporter gene activity in osteosarcoma cells that was detectable at 10 nM in a dose-dependent manner [179]. These erythroidines have also been reported to be present in *E. abyssinica* and thus could be responsible for the estrogenic activity of this plant.

3.5.11. Anticonvulsant and Anxiolytic Activity. The long-known neuropharmacological activity of this plant was the curariform activity which is largely attributed to alkaloids present in it. Erysothrine and erysothrine isolated from the seeds of *E. abyssinica* showed significant curare-like activity both *in vitro* and *in vivo* [132]. The other CNS demonstrated activities of compounds present in *E. abyssinica* include anticonvulsant [180, 181], analgesic [180], and anxiolytic. In another study, erysothrine and erysodine (0, 3, or 10 mg/kg) administered orally exhibited anxiolytic effect in mice with comparable efficacy to diazepam (2 mg/kg) administered intraperitoneally. Using the elevated plus maze (EPM) model, only erysodine (10 mg/kg) increased the percentage of open arm entries and open arm time. In the light-dark transition model (LDTM), both erysodine and erysodine demonstrated anxiolytic-like activity. However, while erysodine (10 mg/kg) increased both times spent in the illuminated compartment and the number of transitions between compartments, erysodine (3 mg/kg) increased the number of transitions only. It was further observed that none of the two alkaloids neither altered the locomotory behaviour (i.e., the number of closed arm entries) of the animals in the EPM [182].

3.6. Toxicity Profile of *E. abyssinica*. Toxicological evaluation of medicinal plants, isolated pure compounds, and corresponding herbal products is one of the key requirements for their approval and licensing as pharmaceutical products by regulatory authorities. This is because apart from possessing pharmacological activity that can be exploited for therapeutic benefits, the same phytochemicals may interact with the same or different receptors and elicit toxicity. Some toxicities may either be dose-dependent or dose-independent. On the other hand, some may be immediate while others delayed. Although no substance can be declared to be completely devoid of toxicity, toxicity tests (acute, subacute, subchronic, and chronic) are used to determine the relative toxicity of potential therapeutic agents.

Despite the huge data regarding the pharmacological potential of *E. abyssinica*, there is a paucity of data regarding its toxicity. The seeds are traditionally known to be poisonous [11]. In an *in vitro* acute toxicity assay using the brine shrimp lethality model, the methanolic and ethanolic extracts of *E. abyssinica* had LC₅₀ ≥ 1000 μg/mL [127] and 997 μg/mL [159], respectively. A related *in vitro* study using the haemolytic assay reported that the hexane (62.5 μg/mL), dichloromethane (62.5 μg/mL), ethyl acetate (62.5 μg/mL), and methanol (125 μg/mL) extracts of this plant showed low percentage haemolysis (15.5, 9.1, 15.4, and 39.7%) of red blood cells [175]. The higher percentage haemolysis observed with the methanol extract was attributed to the higher concentration of methanol extract. *In vitro* results indicated that the extracts were safe within 24 hours of administration.
In a study which determined the in vivo acute toxicity of crude extracts from this plant, it was found out that the median lethal dose (LD₅₀) of leaf and stem bark extracts was above 300 mg/kg body weight. All the mice orally administered with the extracts (100, 200, and 300 mg/kg) survived up to 72 hours and there were no significant behavioural changes between the treatment and control groups [183]. In another study, the methanolic root extract was found to have an oral LD₅₀ of 776.2 mg/kg in mice [126]. As with the previous study, acute toxicity signs became more apparent at the highest doses. But still they were limited to sedation and reduced motor activity. Based on the OECD 2001 guidelines, since the LD₅₀ is greater than 300 mg/kg, it can be inferred that the crude extracts are weakly toxic within 24 hours of a single high dose [184]. It is important to know that the seeds of E. abyssinica contain curare-like alkaloids. Thus, it is believed that, at high doses, these may cause anaesthesia, paralysis, and even death by respiratory failure [185].

In a subacute toxicity evaluation of the extract from this plant, the mice were dosed with 100, 200, and 300 mg/kg of the extract daily for 30 days. There was no significant difference in behaviour and physical and general activity parameters such as water intake, food consumption, and body weight between the treated groups and control group (no extract given) throughout the period of the experiments [183]. However, there were variations in biochemical parameters between the E. abyssinica-treated groups and nontreated group although it was not statistically significant. Particularly the treated group had higher levels of urea and creatinine and lower levels of potassium and sodium. There was also high total and/or conjugated bilirubin associated with E. abyssinica-treated groups. This could probably suggest possible liver insufficiency or interference with bile flow. However, this finding was inconclusive as it could be due to other contributing factors other than the liver. Another study reported that the E. abyssinica (1000 mg/kg) significantly increased the levels of urea and creatinine and level of serum diagnostic enzymes particularly alkaline phosphatase, lactate dehydrogenase, gamma-glutamyltransferase, and alpha-amyrase in treated mice after 28 days of daily oral administration [128]. This probably indicated some degree of impairment of renal, liver, and heart functions. Histopathological evaluation of the tissues of the liver revealed necrotic foci, dilated and congested blood vessels, numerous hepatocytes with double nuclei in view, and infiltration of inflammatory cell, while the kidney tissues showed necrotic foci in the papillary region, loss of tubules in necrotic foci, and vacuolated cells in place of original cells. The liver being the primary detoxifying organ of the body while the kidney being the excretory organ are highly susceptible to damage by phytochemicals present in the extracts/herbal medicines.

The haematological parameters were also slightly altered by extract administration, suggesting an effect on the hematopoietic tissue [183]. As with the biochemical parameters, the assays did not conclusively show haemolysis or other blood-related toxicity of the extracts. In contrast, another study found out that the stem extract (1000 mg/kg) did not significantly alter the haematological indices of the treated rats as compared to the nontreated after 28 days of daily oral administration [128]. It can therefore be inferred that extracts of this plant have minimal toxicity effect on the hematopoietic tissue. Since this plant has been reported to have minimal toxicity on the liver, kidney, and hematopoietic tissue, it should be used with caution in traditional medicine. More evidence regarding its chronic toxicity is needed to guarantee its safety especially in the management of chronic conditions.

3.7. Clinical Studies. We did not find any relevant report reporting results of a clinical trial on either a pharmaceutical product or an herbal product from E. abyssinica. This could be probably due to the huge financial requirement to conduct clinical trials but also other challenges surrounding herbal medicine use.

4. Conclusion and Future Perspectives

E. abyssinica has been proven to harbor useful pharmacologically active phytochemicals against various diseases with significant efficacies although with some minimal toxicity profiles. There is therefore a need to generate more toxicological data about this plant and different isolated phytochemicals so as to generate sufficient evidence as regards their safety for human use. Once proven safe, the plant could provide a cheap and sustainable source of novel molecules for the development of new therapeutic agents for human ailments. To the best of our knowledge, we did not find any E. abyssinica-based pharmaceutical products in the literature, different pharmacopoeia, and drug development pipeline. The active phytochemicals identified could therefore be prioritized and/or optimized for further drug development. There is also a need to standardize and promote rational herbal medicine use through encouraging registration and licensing of products with proven efficacy and safety. Clinical studies utilizing extracts and isolated compounds from E. abyssinica are required. Due to its ethnomedicinal purposes, communities should be sensitized and encouraged to conserve this plant species.

**Abbreviations**

AMPK: Adenosine monophosphate-activated protein kinase
CNS: Central nervous system
E. abyssinica: Erythrina abyssinica Lam. ex. DC.
HIV: Human immunodeficiency virus
LD₅₀: Median lethal dose
MIC/IC₅₀: Minimum inhibitory concentration
PLA₂: Phospholipase A2
WHO: World Health Organization.

**Data Availability**

This is a review article and no raw experimental data were collected. All data generated or analyzed during this study are included in this published article.
Disclosure

This work was initially presented at Natural Products Research Network for Eastern and Central Africa Uganda Chapter (NAPRECA-U) in its virtual seminar held on 24 September 2020.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

The authors are grateful to the World Bank and the Inter-University Council of East Africa (IUCEA) for the scholarship awarded to SBO, SM, MPO, and TO through the Africa Centre of Excellence II in Phytochemicals, Textiles and Renewable Energy (ACE II PTRE) at Moi University, Kenya, which made this communication possible. Our sincere appreciation goes to the preceding authors for their efforts in sharing their research findings on the medicinal values of \textit{E. abyssinica}. This research was supported by the International Foundation for Science (IFS), Stockholm, Sweden, and Organisation for the Prohibition of Chemical Weapons (OPCW) through a grant to Samuel Baker Obakiro (Grant no. I-1-F-6451-1).

References

[1] D. F. Rambo, R. Biegelmeyer, N. S. B. Toson et al., “The genus \textit{Erythrina} \textit{L.}: a review on its alkaloids, preclinical, and clinical studies,” \textit{Phytotherapy Research}, vol. 5, no. 33, pp. 1258–1276, 2019.

[2] A. Nyamukuru, J. R. S. Tabuti, M. Lamorde, B. Kato, Y. Sekagya, and P. R. Aduma, “Medicinal plants and traditional treatment practices used in the management of HIV/ AIDS clients in Mpigi District, Uganda,” \textit{Journal of Herbal Medicine}, vol. 7, pp. 51–58, 2017.

[3] F. Schultz, G. Anywar, C. L. Quave, and L. Garbe, “A bibliographic assessment using the degrees of publication method: medicinal plants from the rural greater mpigi region (Uganda),” \textit{Evidence-Based Complementary and Alternative Medicine}, vol. 2021, Article ID 6661565, 18 pages, 2021.

[4] B. Novotna, Z. Polesny, M. F. Pinto-Basto et al., “Medicinal plants used by ‘root doctors’, local traditional healers in Bié province, Angola,” \textit{Journal of Ethnopharmacology}, vol. 260, Article ID 112662, 2020.

[5] R. Komakech, “\textit{Erythrina abyssynica}. The anti-helminthic plant,” 2018, \url{https://www.southworld.net/erythrina-abyssynica-the-anti-helminthic-plant/}.

[6] F. Patti, Y. Taheri, J. Sharifi-rad, M. Martorell, and W. C. Cho, “\textit{Erythrina suberosa}: ethnopharmacology, phytochemistry and biological activities,” \textit{Medicines}, vol. 6, no. 105, pp. 1–7, 2019.

[7] A. Kumar, S. Lingadurai, A. Jain, and N. Barman, “\textit{Erythrina variegata} Linn: a review on morphology, phytochemistry, and pharmacological aspects,” \textit{Pharmacognosy Reviews}, vol. 4, no. 8, pp. 147–152, 2010.

[8] M. M. I. Minja, “Medicinal plants used in the promotion of animal health in Tanzania,” \textit{Revue Scientifique et Technique de l’OIE}, vol. 13, no. 3, pp. 905–925, 1994.

[9] E. Bein, B. Habte, A. Jaber, A. Birnie, and B. Tengnas, “Useful trees and shrubs useful trees and shrubs in eritrea: identification, propagation and management for agricultural and pastoral communities,” \textit{Technical Handbook No. 12}, p. 422, Regional soil conservation Unit, Nairobi, Kenya, 1996.

[10] C. Orwa, A. Mutua, R. Kindt, R. Jammnadass, and S. Anthony, “Agroforestry database: a tree reference and selection guide version 4.0.,” 2009, \url{http://apps.worldagroforestry.org/treebd/AFTPDFS/Erythrina_abyssinica.PDF}.

[11] B. Katende, A. Birnie, and B. Tengnàs, \textit{Useful Trees and Shrubs for Uganda—Identification, Propagation, and Management for Agricultural and Pastoral Communities}, Regional Soil Conservation Unit, Nairobi, Kenya, 1995.

[12] T. Omara, A. K. Kiprop, R. C. Ramkat et al., “Medicinal plants used in traditional management of cancer in Uganda: a review of ethnobotanical surveys, phytochemistry, and anticancer studies,” \textit{Evidence-Based Complementary and Alternative Medicine}, vol. 2020, Article ID 3529081, 26 pages, 2020.

[13] J. O. Kokwaro, \textit{“Medicinal Plants of East Africa}}, East Africa Literature Bureau, Nairobi, Kenya, 3rd edition, 1976.

[14] J. R. S. Tabuti, K. A. Lye, and S. S. Dhillon, “Traditional herbal drugs of Bulamogi, Uganda: plants, use and administration,” \textit{Journal of Ethnopharmacology}, vol. 88, no. 1, pp. 19–44, 2003.

[15] J. O. Kokwaro, \textit{“Medicinal Plants of East Africa”}}, Kenya Literature Bureau, Nairobi, Kenya, 1993.

[16] J. O. Kokwaro, \textit{Medicinal Plants of East Africa}}, East Africa Education Publishers, Nairobi, Kenya, 1994.

[17] T. Omara, “Plants used in antivenom therapy in rural Kenya: ethnobotany and future perspectives,” \textit{Journal of Toxicology}, vol. 2020, Article ID 1828521, 9 pages, 2020.

[18] T. Omara, “Antimalarial plants used across kenyan communities,” \textit{Evidence-Based Complementary and Alternative Medicine}, vol. 2020, Article ID 4538602, 31 pages, 2020.

[19] J. K. Musau, J. M. Mbaria, and D. W. Gakuya, “The antibacterial activity of some medicinal plants used in Meru Central District, Kenya,” \textit{The Kenya Veterinarian}, vol. 35, no. 1, pp. 18–24, 2011.

[20] D. A. Hines and K. Eckman, “Indigenous multipurpose multipurpose trees of Tanzania: uses and economic benefits for people,” FO:Misc/93/9 Working Paper, Vol. 275, Food and Agriculture Organization of the United Nations, Rome, Italy, August 1993.

[21] S. M. Maregesi and R. Mwakalukwa, “Ethnopharmacological study on medicinal plants used to treat infectious diseases in the rungwe district, Tanzania,” \textit{International Journal of Medicinal Plants and Natural Products}, vol. 1, no. 3, pp. 15–23, 2015.

[22] D. C. Ramathal and O. D. Ngassapa, “Medicinal plants used by rwandese traditional healers in refugee camps in Tanzania,” \textit{Pharmaceutical Biology}, vol. 39, no. 2, pp. 132–137, 2001.

[23] M.-J. Mukazayire, V. Minani, C. K. Ruffo, E. Bizuru, C. Stévigny, and P. Duez, “Traditional phytotherapy remedies used in Southern Rwanda for the treatment of liver diseases,” \textit{Journal of Ethnopharmacology}, vol. 138, no. 2, pp. 415–431, 2011.

[24] M. Chagnon, “Inventaire pharmacologique general des plantes medicinales rwandaises,” \textit{Journal of Ethnopharmacology}, vol. 12, no. 3, pp. 239–251, 1984.

[25] Y. Boily and L. Van Puyvelde, “Screening of medicinal plants of Rwanda (Central Africa) for antimicrobial activity,” \textit{Journal of Ethnopharmacology}, vol. 16, no. 1, pp. 1–13, 1986.
Evidence-Based Complementary and Alternative Medicine

[26] R. Mäkere-Faniyo, L. Van Puyvelde, A. Mutwewingabo, and F. X. Habiyaranye, "Study of Rwandese medicinal plants used in the treatment of diarrhoea I," Journal of Ethnopharmacology, vol. 26, no. 2, pp. 101–109, 1989.

[27] M. S. Musa, F. E. Abdelrasool, E. A. Elsheikh et al., "Ethnobotanical study of medicinal plants in the blue nile state, south-eastern Sudan," Journal of Medicinal Plants Research, vol. 5, no. 17, pp. 287–4297, 2011.

[28] H. Ali, G. M. König, S. A. Khalid, A. D. Wright, and R. Kaminsky, "Evaluation of selected Sudanese medicinal plants for their in vitro activity against hemostaggluates, selected bacteria, HIV-1-RT and tyrosine kinase inhibitory, and for cytotoxicity," Journal of Ethnopharmacology, vol. 83, no. 3, pp. 219–228, 2002.

[29] B. Yemane, G. Medhanie, and K. S. Reddy, "Survey of some common medicinal plants used in Eritrean folk medicine," American Journal of Ethnomedicine, vol. 112, pp. 865–876, 2018.

[30] World Health Organization, "WHO global report on traditional and complementary medicine," 2019, https://www.who.int/traditional-complementary-integrative-medicine/WhoGlobalReportOnTraditionalAndComplementaryMedicine2019.pdf?ua=1.

[31] P. Tugume, E. K. Kakudidi, M. Buyinza et al., "Ethnobotanical survey of medicinal plant species used by communities around Mabira central forest reserve, Uganda," Journal of Ethnobiology and Ethnomedicine, vol. 12, no. 1, p. 28, 2016.

[32] L. N. Silva, K. R. Zimmer, A. J. Macedo, and D. S. Trentin, "plant natural products targeting bacterial virulence factors," Chemical Reviews, vol. 16, no. 116, pp. 9162–9236, 2016.

[33] A. Bauer and M. Brönstrup, "Industrial natural product chemistry for drug discovery and development," Natural Product Reports, vol. 31, no. 1, pp. 35–60, 2014.

[34] N. N. Ihekwe and S. J. Ameh, "Plant natural products research in tuberculosis drug discovery and development: a situation report with focus on Nigerian biodiversity," African Journal of Biotechnology, vol. 13, pp. 2307–2320, 2014.

[35] C. B. Naman, C. A. Leber, and W. H. Gerwick, "modern natural products drug discovery and its relevance to biodiversity conservation," in Microbial Resources: From Functional Existence in Nature to Applications, 2017.

[36] J. M. Sanders, M. L. Monogue, T. Z. Jodlowski, and J. B. Cutrell, "Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review," JAMA, vol. 323, pp. 1824–1836, 2020.

[37] L. Bunalema, G. W. Fotso, P. Waako, J. R. S. Tabuti, and S. O. Yebao, "Potential of Zanthoxylum leprieurii as a source of active compounds against drug resistant Mycobacterium tuberculosis," BMC Complementary and Alternative Medicine, vol. 17, p. 89, 2017.

[38] S. B. Okakiro, L. Bunalema, E. Nyatia, and J. P. Waako, "Uceroigenetic potential of Eucalyptus globulus L. leaf extract in Wistar albino rats," Journal of Pharmacology and Toxicology, vol. 4, pp. 46–51, 2018.

[39] G. Anywar, E. Kakudidi, R. Byamukama, J. Mukonzo, A. Schubert, and H. Oryem-Origa, "Indigenous traditional knowledge of medicinal plants used by herbalists in treating opportunistic infections among people living with HIV/AIDS in Uganda," Journal of Ethnopharmacology, vol. 246, Article ID 112205, 2020.

[40] M. W. Kirika, J. W. Kahia, L. N. Diby, E. M. Njagi, C. Dadjo, and C. Kouame, "Micropropagation of an endangered medicinal and indigenous multipurpose tree species: Erythrina abyssinica," HortScience, vol. 50, no. 5, pp. 738–743, 2015.

[41] B. Reubens, C. Moeremans, J. Poesen et al., "Tree species selection for land rehabilitation in Ethiopia: from fragmented knowledge to an integrated multi-criteria decision approach," Agroforestry Systems, vol. 82, no. 3, pp. 303–330, 2011.

[42] L. D. Ambrosio, R. Centis, G. Sotgiu, E. Pontali, A. Spanevello, and G. B. Migliori, "New anti-tuberculosis drugs and regimens: 2015 update," ERJ Open Research, vol. 1, pp. 00010–00015, 2015.

[43] T. H. Bekalo, S. D. Woodmatas, and Z. A. Woldemariam, "An ethnobotanical study of medicinal plants used by local people in the lowlands of Konta Special Woreda, southern nations, nationalities and peoples regional state, Ethiopia," Journal of Ethnobiology and Ethnomedicine, vol. 5, p. 26, 2009.

[44] D. Mwchahary and D. C. Nath, "Deforestation and its impact on ethno-medical practices among Bodo tribe of kokrajhar district in Assam, India," Journal of Environmental Science, Computer Science and Engineering & Technology, vol. 4, no. 4, pp. 961–979, 2015.

[45] L. Chandra De, "Bio-Diversity and conservation of medicinal and aromatic plants," Advances in Plants and Agricultural Research, vol. 5, no. 4, pp. 561–566, 2016.

[46] J. D. Gafna, K. Dolos, I. O. Mahiri, J. G. Mahiri, and J. A. Obando, "Diversity of medicinal plants and anthropogenic threats in the Samburu central sub-county of Kenya," African Journal of Traditional, Complementary and Alternative Medicine, vol. 14, pp. 72–79, 2017.

[47] S. A. He and H. Sheng, Utilization and Conservation of Medicinal Plants in China with Special Reference to Atracyloides lanecia, pp. 161–168, University of Pennsylvania Press, Philadelphia, PA, USA, 1998.

[48] D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and The PRISMA Group, "Preferred reporting Items for systematic reviews and meta-analyses: the PRISMA statement," PLoS Medicine, vol. 6, Article ID e100097, 2009.

[49] A. Yenesew, M. Induli, S. Derese et al., "Anti-plasmodial flavonoids from the stem bark of Erythrina abyssinica," Phytochemistry, vol. 65, no. 22, pp. 3029–3032, 2004.

[50] J. Nasimolo, S. G. Kiama, P. K. Gathumbi, A. N. Makanya, and J. M. Kagira, "Erythrina abyssinica prevents meningencephalitis in chronic Trypanosoma brucei brucei mouse model," Metabolic Brain Disease, vol. 29, no. 2, pp. 509–519, 2014.

[51] S. A. Tree, "Erythrina abyssinica," 2020, https://treesa.org/erythrina-abyssinica/.

[52] N. Laurent and S. A. O. Chamshama, "Studies on the germination of erythrina abyssinicaa from juniperus procera," International Tree Crops Journal, vol. 4, no. 4, pp. 291–298, 1987.

[53] R. Aerts, "Erythrina abyssinica Lam. ex DC.,” in Protoco (7): Timbers/Bois D’oeuvre 1. [CDRom], PROTA, D. Loppe, A. A. Oteng-Amoako, and M. Brink, Eds., Wageningen, The Netherlands, 2008.

[54] N. Dharani, Field Guide to Common Trees & Shrubs of East Africa, Random Struik Publishers, Cape Town, South Africa, 3rd edition, 2019.

[55] N. Dharani and A. Yenesew, Medicinal Plants of East Africa, Drongo Editing & Publishing, Nairobi, Kenya, 2010.

[56] G. Wetangula, J. A. Raini, and I. Munyeki, "Vegetation types and diversity in Menengai Caldera Geothermal Project Area, Kenya,” in Proceedings of the Presentation at Short Course X on Exploration for Geothermal Resources, Organized by UNU-GTP, GDC and KenGen, at Lake Bogoria and Lake
Evidence-Based Complementary and Alternative Medicine

Naivasha, Kenya, Nairobi, Kenya, November-December 2015.

[57] A. C. Hamilton, A Field Guide to Uganda Forest Trees, Makerere University Press, Kampala, Uganda, 1981.

[58] G. N. Njoroge and R. W. Bussman, “Diversity and utilization of antimalarial ethnophytotherapeutic remedies among the Kikuyus (Central Kenya),” Journal of Ethnobiology and Ethnomedicine, vol. 2, no. 8, p. 7, 2006.

[59] M. M. D. Mohammed, N. A. Ibrahim, N. E. Awad et al., “Anti-HIV-1 and cytotoxicity of the alkaloids of Erythrina abyssinica Lam. growing in Sudan,” Natural Product Research, vol. 26, no. 17, pp. 1565–1575, 2012.

[60] T. Manyarara, J. Chifamba, and F. Taragarira, “Antifungal activity of ziziphus mucronata and Erythrina abyssinica bark crude extracts on Cryptococcus neoformans and Candida albicans species,” British Journal of Pharmaceutical Research, vol. 10, no. 3, pp. 1–11, 2016.

[61] F. M. Rodegem, “Dictionnaire Rundi-Français. Annales du Musée royal de l'Afrique centrale, Tervuren (Belgique), Série in –8°, Sc. humaines, 69, [Rundi-French dictionary, Royal Museum for Central Africa edition, Series: royal Museum for Central Africa, Tervuren, Belgium. Annals. Series in-8. Humanités, No. 69],” 1970.

[62] G. Mosisa, “Evaluation of stem bark of erythrina abyssinica by crude extracts on antimalarial and termiticidal principles,” M.Sc. thesis, Jimma University, Jimma, Ethiopia, 2017.

[63] J. Ndamba, N. Nyazema, N. Makaza, C. Anderson, and K. C. Kaondera, “Traditional herbal remedies used for the treatment of urinary schistosomiasis in Zimbabwe,” Journal of Ethnopharmacology, vol. 42, no. 2, pp. 125–132.

[64] K. Majid, B.-I. Gilbert, and L. S. Jeremiah, “Role of Acacia and Erythrina trees in forest regeneration by vertebrate seed dispersers in Kibale National Park, Uganda,” African Journal of Ecology, vol. 49, no. 2, pp. 189–198, 2011.

[65] G. Nyberg and P. Högborg, “Effects of young agroforestry trees on soils in on-farm situations in western Kenya,” Agroforestry Systems, vol. 32, no. 1, pp. 45–52, 1995.

[66] A. Abay, “Nitrogen release dynamics of Erythrina abyssinica and Erythrina brucei litters as influenced by their biochemical composition,” African Journal of Plant Science, vol. 12, no. 12, pp. 331–340, 2018.

[67] V. Ingram, R. Kirui, J. Hitimana et al., “Trees and plants for bees and beekeepers in the Upper Mara Basin,” in Guide to Useful Melliferous Trees and Crops for Beekeepers Wageningen University & Research, Wageningen, Netherlands, 2017.

[68] E. K. Kakudidi, “Cultural and social uses of plants from and around kibale national park, Western Uganda,” African Journal of Ecology, vol. 42, no. 18, pp. 114–118, 2004.

[69] D. T. Ndinhé, “Antidiabetic potential of Erythrina abyssinica via protein tyrosine phosphate 1B inhibitory activity,” in Emerging Trends in Chemical Sciences, P. Ramasami, M. Gupta Bhowon, S. Jhaumeer Laulloo, and H. Li Kam Wah, Eds., pp. 377–389, Springer, Cham, Switzerland, 2016.

[70] A. Larbi, D. Thomas, and J. Hanson, “Forage potential of Erythrina abyssinica: intake, digestibility and growth rates for stall-fed sheep and goats in southern Ethiopia,” Agroforestry Systems, vol. 21, no. 3, pp. 263–270, 1993.

[71] A. Larbi, O. I. Kurdi, A. N. Said, and J. Hanson, “Classification of Erythrina provenances by rumen degradation characteristics of dry matter and nitrogen,” Agroforestry Systems, vol. 33, no. 2, pp. 153–163, 1996.

[72] F. Schultz, G. Anywar, B. Wack, C. L. Quave, and L.-A. Garbe, “Ethnobotanical study of selected medicinal plants traditionally used in the rural Greater Mpigi region of Uganda,” Journal of Ethnopharmacology, vol. 256, Article ID 112742, 2020.

[73] D. Lacroix, S. Prado, D. Kamoga et al., “Antiplasmodial and cytotoxic activities of medicinal plants traditionally used in the village of Kiohima, Uganda,” Journal of Ethnopharmacology, vol. 133, no. 2, pp. 850–855, 2011.

[74] J. Namukobe, J. M. Kasenene, B. T. Kiremire et al., “Traditional plants used for medicinal purposes by local communities around the Northern sector of Kibale National Park, Uganda,” Journal of Ethnopharmacology, vol. 136, no. 1, pp. 236–245, 2011.

[75] N. Mukungu, K. Abuga, F. Okalebo, R. Ingwela, and J. Mwangi, “Medicinal plants used for management of malaria among the Luhya community of Kakamega East sub-County, Kenya,” Journal of Ethnopharmacology, vol. 194, pp. 98–107, 2016.

[76] P. G. Kareru, G. M. Kenji, A. N. Gachanja, J. M. Keriko, and G. Murungi, “Traditional medicines among the Embu and Mbeere people of Kenya,” African Journal of Traditional Complementary and Alternative Medicine, vol. 4, pp. 75–86, 2007.

[77] P. Nalumansi, M. Kamatenesi-Mugisha, and A. Godwin, “Medicinal plants used in paediatric health care in namungului sub county, iganga district, Uganda,” Nova Journal of Medical and Biological Sciences, vol. 03, no. 02, pp. 1–10, 2014.

[78] F. Kasali, A. O. Mahano, D. S. Nyakabwa et al., “Ethnopharmacological survey of medicinal plants used against malaria in bukavu city (D.R. Congo),” European Journal of Medicinal Plants, vol. 4, no. 1, pp. 29–44, 2014.

[79] J. Nankaya, N. Gichuki, C. Lukhoba, and H. Balslev, “Medicinal plants of the Maasai of Kenya: a review,” Plants, vol. 9, no. 1, pp. 44, 2019.

[80] O. Amuka, A. K. Machocho, P. K. Mbugua, and P. O. Okemo, “Ethnobotanical survey of selected medicinal plants used by the ogiek communities in Kenya against microbial infections,” Ethnobotany Research and Applications, vol. 12, pp. 627–641, 2014.

[81] S. V. Okello, R. O. Nyunja, G. W. Netondo, and J. C. Onyango, “Ethnobotanical study of medicinal plants used by Sabaots of Mt. Elgon Kenya,” African Journal of Traditional, Complementary and Alternative Medicine, vol. 7, no. 1, pp. 1–10, 2010.

[82] M. Ichimaru, M. Moriyasu, Y. Nishiyama et al., “Structural elucidation of new flavanones isolated from Erythrina abyssinica,” Journal of Natural Products, vol. 59, no. 12, pp. 1113–1116, 1996.

[83] D. Njam, J. T. Mbafer, Z. T. Fomum et al., “Anti-inflammatory activities of two flavanones, sigmoidin A and sigmoidin B, from Erythrina sigmoida,” Planta Medica, vol. 70, no. 2, pp. 104–107, 2004.

[84] E. Odongo, N. Mungai, P. Mutai, E. Karumi, J. Mwangi, and J. Omale, “Ethnobotanical survey of medicinal plants used in Kakamega County, Western Kenya,” Applied Medical Research, vol. 4, no. 1, pp. 22–40, 2018.

[85] N. Shiracko, B. O. Owuor, M. M. Gakubi, and W. Wanza, “A survey of ethnobotany of the AbaWanga people in Kakamega county, Western province of Kenya,” Indian Journal of Traditional Knowledge, vol. 15, pp. 93–102, 2016.

[86] W. Kipkore, B. Wanjohi, H. Ronro, and G. Kigen, “A study of the medicinal plants used by the Marakwet community in Kenya,” Journal of Ethnobiology and Ethnomedicine, vol. 10, no. 1, p. 24, 2014.
Evidence-Based Complementary and Alternative Medicine

[87] D. Musinguzi, A. Tumushabe, K. Sekabira, T. A. Basamba, and D. Byarugaba, "Medicinal plants use in and around Kalinzu central forest reserve, Western Uganda," *Journal of Medicinal Plants Studies*, vol. 5, no. 6, pp. 44–49, 2017.

[88] A. Maroyi, "An ethnobotanical survey of medicinal plants used by the people in Nhema communal area, Zimbabwe," *Journal of Ethnopharmacology*, vol. 136, no. 2, pp. 347–354, 2011.

[89] D. Oilla, R. Bukenya-Ziraba, and D. Kamoga, "Bio-prospective studies on medicinal plants used in the treatment of poultry diseases in Uganda," *Research Journal of Pharmacology*, vol. 1, pp. 56–60, 2007.

[90] J. Cortez, E. Rosário, J. E. Pires et al., "Antimicrobial storage and antibiotic knowledge in the community: a cross-sectional pilot study in north-western Angola," *International Journal of Infectious Diseases*, vol. 60, pp. 83–87, 2017.

[91] D. K. Kariuki, J. O. Miaron, J. Mugwero, and L. O. Kerubo, "Antibacterial activity of five medicinal plant extracts used by the Maasai people of Kenya," *BEST: International Journal of Humanities, Arts, Medicine and Sciences*, vol. 2, no. 7, pp. 1–6, 2014.

[92] K. N. Kimathi, P. A. Ogutu, C. Mutai, and P. Jeruto, "Knowledge on plants used traditionally in the treatment of tuberculosis in Africa," *Phytotherapy Research*, vol. 24, no. 1, pp. 150–153, 2010.

[93] W. Musila, D. Kisangau, and J. Muema, "Conservation status and use of medicinal plants by traditional medical practitioners in Machakos District, Kenya," in *Proceedings of the Indigenous Knowledge Conference*, pp. 27–29, Eastern Kenya University, Kitui, Kenya, 2004.

[94] A. Marume, S. Khoza, G. Matope et al., "Wound healing properties of selected plants used in ethnoveterinary medicine," *Frontiers in Pharmacology*, vol. 8, pp. 1–10, 2017.

[95] M. Gelfand, S. Mavi, R. B. Drummond, and B. Ndemera, *The Traditional Medical Practitioner in Zimbabwe: His Principles of Practice and Pharmacopoeia (Zambeziana)*, Vol. 17, Mambo Press, Gweru, Zimbabwe, 1985.

[96] L. Bunalema, S. Obakiro, J. R. S. Tabuti, and P. Waako, "Knowledge on plants used traditionally in the treatment of tuberculosis in Uganda," *Journal of Ethnopharmacology*, vol. 151, no. 2, pp. 999–1004, 2014.

[97] J. A. Orodho, C. Kirimuhuzya, J. N. Otieno, J. J. Magadula, and P. Okemo, "Local management of tuberculosis by traditional medicine practitioners in lake Victoria region," *The Open Complementary Medicine Journal*, vol. 3, no. 1, pp. 1–9, 2011.

[98] D. P. Kisangau, H. V. M. Lyaruu, K. M. Hosea, and C. C. Joseph, "Use of traditional medicines in the management of HIV/AIDS opportunistic infections in Tanzania: a case in the Bukoba rural district," *Journal of Ethnobiology and Ethnomedicine*, vol. 3, pp. 1–8, 2007.

[99] J. R. S. Tabuti, C. B. Kukunda, and P. J. Waako, "Medicinal plants used by traditional medicine practitioners in the treatment of tuberculosis and related ailments in Uganda," *Journal of Ethnopharmacology*, vol. 127, no. 1, pp. 130–136, 2010.

[100] C. G. Waigate, J. M. Mbaria, D. W. Gakyua et al., "Screening of some Kenyan medicinal plants for antibacterial activity," *Phytotherapy Research*, vol. 24, no. 1, pp. 150–153, 2009.

[101] S. Asimwe, M. Kamatenesi-Mugisha, A. Namutebi, A.-K. Borg-Karlsson, and P. Musiimenta, "Ethnobotanical study of nutri-medicinal plants used for the management of HIV/AIDS opportunistic ailments among the local communities of Western Uganda," *Journal of Ethnopharmacology*, vol. 150, no. 2, pp. 639–648, 2013.

[102] M. Lamorde, J. R. S. Tabuti, C. Obua et al., "Medicinal plants used by traditional medicine practitioners for the treatment of HIV/AIDS and related conditions in Uganda," *Journal of Ethnopharmacology*, vol. 130, no. 1, pp. 43–53, 2010.

[103] M. Shehu, I. Bello, N. Abdulkardir et al., "Utilization of medicinal plants used in the management of HIV/AIDS opportunistic infections in Njeru sub-county, Buikwe district, Uganda," *MOJ Bioequivalence Bioavailability*, vol. 5, no. 1, pp. 66–72, 2018.

[104] M. Kamatenesi-Mugisha and H. Oryem-Origa, "Medicinal plants used to induce labour during childbirth in Western Uganda," *Journal of Ethnopharmacology*, vol. 109, no. 1, pp. 1–9, 2007.

[105] J. K. Muthee, D. W. Gakyua, J. M. Mbaria, P. G. Kereru, C. M. Mulei, and F. K. Njonge, "Ethnobotanical study of anthelmintic and other medicinal plants traditionally used in Loitoktok district of Kenya," *Journal of Ethnopharmacology*, vol. 135, no. 1, pp. 15–21, 2011.

[106] G. Kigen, A. Maritim, F. Some et al., "Ethnopharmacological survey of the medicinal plants used in Tindiret, Nandi county, Kenya," *African Journal of Traditional, Complementary and Alternative Medicines*, vol. 13, no. 3, pp. 156–168, 2016.

[107] S. M. Maregesi, O. D. Ngassapa, L. Pieters, and A. J. Vlietinck, "Ethnopharmacological survey of the Bunda district, Tanzania: plants used to treat infectious diseases," *Journal of Ethnopharmacology*, vol. 113, no. 3, pp. 457–470, 2007.

[108] S. Augustino and P. R. Gilla, "Medicinal plants in urban districts of Tanzania: plants, gender roles and sustainable use," *International Forestry Review*, vol. 7, no. 1, pp. 44–58, 2005.

[109] S. Augustino, J. B. Hall, F. B. S. Makonda, and R. C. Ishengoma, "Medicinal resources of the miombo woodlands of urumwa, Tanzania: plants and its uses," *Journal of Medicinal Plants Research*, vol. 5, no. 27, pp. 6352–6372, 2011.

[110] E. O. Owenga, A. Hensel, A. Shitandi, and F. M. Goycoolea, "Ethnobotanical survey of traditionally used medicinal plants for infections of skin, gastrointestinal tract, urinary tract and the oral cavity in Borabu sub-county, Nyamira county, Kenya," *Journal of Ethnopharmacology*, vol. 176, pp. 508–514, 2015.

[111] F. A. Hamill, S. Apio, N. K. Mubiru et al., "Traditional herbal drugs of southern Uganda," *Journal of Ethnopharmacology*, vol. 87, no. 1, pp. 15–19, 2003.

[112] A. J. Vlietinck, L. Van Hoof, J. Lasure, D. V. Berghe, F. A. Hamill, S. Apio, and N. K. Mubiru, "Traditional herbal drugs of southern Uganda," *MOJ Bioequivalence Bioavailability*, vol. 5, no. 1, pp. 31–47, 1995.

[113] N. M. Piero, N. J. Murugi, M. C. Kibiti et al., "Hypoglycemic activity of some Kenyan medicinal plants traditionally used to manage diabetes mellitus in eastern province," *Journal of Diabetes and Metabolism*, vol. 2, p. 155, 2015.

[114] B. Amuri, M. Maseho, L. Simbi, P. Okusa, P. Duez, and K. Byanga, "Hypoglycemic and antihyperglycemic activities of nine medicinal herbs used as anti diabetic in the region of lubumbashi (DR Congo)," *Phytotherapy Research*, vol. 31, no. 7, pp. 1029–1033, 2017.

[115] M. E. Parker, S. Chabot, B. J. Ward, and T. Johns, "Traditional dietary additives of the Maasai are antiviral against the..."
measles virus,” *Journal of Ethnopharmacology*, vol. 114, no. 2, pp. 146–152, 2007.

[116] G. N. Njoroge and J. W. Kibunga, “Herbal medicine acceptance, sources and utilization for diarrhoea management in a cosmopolitan urban area (Thika, Kenya),” *African Journal of Ecology*, vol. 45, no. s1, pp. 65–70, 2007.

[117] S. C. Chhabra, F. C. Uiso, and E. N. Mshiu, “Phytochemical screening of Tanzanian medicinal plants. I,” *Journal of Ethnopharmacology*, vol. 11, no. 2, pp. 157–179, 1984.

[118] P. E. Glover, J. Stewart, and M. D. Gwynne, “Masai and kipsigis notes on East African plants,” *East African Agricultural and Forestry Journal*, vol. 32, no. 2, pp. 200–207, 1966.

[119] M. Gakuubi and W. Wanzala, “A survey of plants and plant products traditionally used in livestock health management in Buuri district, Meru County, Kenya,” *Journal of Ethnobiology and Ethnomedicine*, vol. 8, no. 1, p. 39, 2012.

[120] P. Wasswa and D. Olila, “The in-vitro ascaricidal activity of selected indigenous medicinal plants used in ethno veterinary practices in Uganda,” *African Journal of Traditional, Complementary, and Alternative Medicine*, vol. 3, no. 2, pp. 94–103, 1995.

[121] R. Ntume and U. G. Anywar, “Ethnopharmacological survey of medicinal plants used in the treatment of ascaries in Central Uganda,” *Current Life Science*, vol. 1, pp. 6–14, 2015.

[122] Rufford, *Medicinal Plants of Baringo, Kenya*, https://www.rufford.org/files/19802-1%20Medicinal%20Plants%20of%20Baringo,%20Kenya.pdf, 2021.

[123] C. Lagu and F. I. B. Kayanja, “In vitro antimicrobial activity of crude extracts of Erythrina abyssinica and capsicum annum in poultry diseases control in the South western agro-ecological zone of Uganda. A bird’s-eye view,” *Veterinary Medicine*, pp. 597–614, 2012.

[124] C. Lagu and F. I. B. Kayanja, “The in Vitro Antihelminthic Efficacy of Erythrina Abyssinica Extracts on Ascaridia Galli,” Intech Open, London, UK, Rufford Organization, Nairobi, Kenya, 2013.

[125] R. Rajakrishnan, R. Lekshmi, P. B. Benil et al., “Phytochemical evaluation of roots of Plumbago zeylanica L. and assessment of its potential as a nephroprotective agent,” *Saudi Journal of Biological Sciences*, vol. 24, no. 4, pp. 760–766, 2017.

[126] L. Bunalema, C. Kirimuhuzya, J. R. S. Tabuti et al., “xY#he in Vitro Antihelminthic Efficacy of Erythrina Abyssinica Extracts on Ascaridia Galli,” Intech Open, London, UK, Rufford Organization, Nairobi, Kenya, 2013.

[127] T. Munodawafa, S. Moyo, B. Chipurura, and L. Chagonda, “Brine shrimp lethality bioassay of some selected Zimbabwean traditional medicinal plants,” *International Journal of Phytopharmacy*, vol. 7, pp. 229–232, 2014.

[128] A. A. Koparde, “Phyto active compounds from herbal plant extracts: its extraction, isolation and characterization,” *World Journal of Pharmaceutical Research*, vol. 6, no. 8, pp. 1186–1205, 2017.

[129] A. Altemimi, N. Lakhsassi, A. Bahrarouei et al., “Phytochemicals: extraction, isolation, and identification of bioactive compounds from plant extracts,” *Plants*, vol. 6, no. 4, 2017.
abysynica Lam and their cytotoxic effects,” *Phytochemistry Letters*, vol. 13, pp. 59–67, 2015.

[148] H. Kamusisi, A. T. Pedersen, Ø. M. Andersen, and B. Kiremire, “Kaempferol 3-O-(2-O-ß-D-Glucopyranosyl-6-O-a-L-Rhamnopyranosyl-ß-D-Glucopyranoside) from the african plant Erythrina abyssinica,” *International Journal of Pharmaceutognosy*, vol. 34, no. 5, pp. 370–373, 1996.

[149] W. M. Kone, K.-N. E. Solange, and M. Dosso, “Assessing sub-saharian Erythrina for efficacy; traditional uses, biological activities and phytochemistry,” *Pakistan Journal of Biological Sciences*, vol. 14, no. 10, pp. 560–571, 2011.

[150] M. Wink, “Evolution of secondary metabolites in legumes (Fabaceae),” *South African Journal of Botany*, vol. 89, pp. 164–175, 2013.

[151] J. C. M. Barreira, T. Visnevsci-Necrasov, G. Pereira, E. Nunes, and M. B. P. P. Oliveira, “Phytochemical profiling of underexploited Fabaceae species: insights on the ontogenic and phylogenetic effects over isoflavone levels,” *Food Research International*, vol. 100, pp. 517–523, 2017.

[152] K. D. Hill, *The Erythrina Alkaloids*, pp. 483–514, Princeton University, Princeton, NJ, USA, 1957.

[153] C. Zhuang, W. Zhang, C. Sheng, W. Zhang, C. Xing, and Z. Miao, “Chalcone: a privileged structure in medicinal chemistry,” *Chemical Reviews*, vol. 117, no. 12, pp. 7762–7810, 2017.

[154] C. Stevenson and N. Aslam, *Studies in Natural Product Chemistry*, Vol. 41, Elsevier, Amsterdam, Nethelands, 1st edition, 2006.

[155] L. Zhang, J. Zhang, Z. Ye, D. M. Townsend, and K. D. Tew, “Pharmacology of ME-344, a novel cytotoxic isoflavone,” *Advances in Cancer Research*, vol. 142, pp. 187–207, 2019.

[156] A. Zuiter, “Flavanones proanthocyanidin: chemistry and biology: from phenolic compounds to proanthocyanidins extraction techniques and applications: food and beverage,” in *Chemistry, Molecular Sciences and Chemical Engineering*, 2014.

[157] T. T. Dao, P. H. Nguyen, P. T. Thuong et al., “Pterocarps with inhibitory effects on protein tyrosine phosphatase 1B from Erythrina lysistemon Hutch,” *Phytochemistry*, vol. 70, no. 17-18, pp. 2053–2057, 2009.

[158] D. Awoouafack, P. Tane, V. Kuet et al., “Susquiterpenes from the medicinal plants of Africa,” *Medicinal Plants Research. African Pharmacology and Chemistry*, pp. 33–103, 2013.

[159] D. R. Kamadayaapa, M. M. Gondwe, M. Shauli, C. Sewani-Rusike, and B. Nkch-Chungag, “Evaluation of anti-diabetic and antioxidant effects of ethanolic leaf extract of Erythrina Abyssinica Lam. Ex DC,” *Asian Journal of Pharmacy and Clinical Research*, vol. 11, no. 8, pp. 300–306, 2018.

[160] P. H. Nguyen, T. V. T. Le, P. T. Thuong et al., “Cytotoxic and PTPIβ inhibitory activities from Erythrina abyssinica,” *Bioorganic & Medicinal Chemistry Letters*, vol. 19, no. 23, pp. 6745–6749, 2009.

[161] B. N. Nkch-chungag, S. Tiya, J. T. Mbafor, E. J. Ndebia, and J. E. Iputo, “Effects of the methanol extract of Erythrina abyssinica on hot flashes in ovariectomized rats,” *African Journal of Biotechnology*, vol. 12, no. 6, pp. 598–601, 2013.

[162] F. K. Macharia, P. W. Mwangi, A. Yenesew et al., “Hepatoprotective effects of erythrina abyssinica lam ex dc against non alcoholic fatty liver disease in sprague dawley rats,” *BioRxiv*, pp. 577–607, 2019.

[163] A. Yenesew, H. M. Akala, H. Twinomuhwezi et al., “The antiplasmodial and radical scavenging activities of flavonoids of Erythrina burttii,” *Acta Tropica*, vol. 123, no. 2, pp. 123–127, 2012.

[164] D. W. Onyango and J. O. Midiwo, “In vivo evaluation of antimalarial activity of stem and root extracts of Erythrina abyssinica,” *European Journal of Medicinal Plants*, vol. 27, no. 4, pp. 1–5, 2019.

[165] R. M. Marita, C. K. P. O. Ogol, N. O. Ogue, and P. O. Okemo, “Antitubercular and phytochemical investigation of methanol extracts of medicinal plants used by the Samburu community in Kenya,” *Tropical Journal of Pharmacy Research*, vol. 9, pp. 379–385, 2010.

[166] J. Abber, P. E. Ogwanga, N. Anyama, and C. O. Ajayi, “In vitro anti-tuberculous study on the combination of extracts of stem-bark of Erythrina abyssinica Lam. ex DC and conventional drugs,” *Journal of Pharmacognosy and Phytochemistry*, vol. 8, no. 3, pp. 2708–2711, 2019.

[167] K. Koriz, C. Bi, C. Kiyukia, and C. Mutai, “Antimicrobial activities of Cluitia abyssinica and Erythrina abyssinica plants extracts used among the Kipsigis community of Bomet district in Kenya,” *Natural Products*, vol. 7, no. 5, pp. 247–252, 2011.

[168] C. C. N. Pillay, A. K. Jäger, D. A. Mulholland, and J. Van Staden, “Cyclooxygenase inhibiting and anti-bacterial activities of South African Erythrina species,” *Journal of Ethnopharmacology*, vol. 74, no. 3, pp. 231–237, 2001.

[169] D. Njamen, E. Tallia, J. T. Mbafer et al., “Anti-inflammatory activity of erycristagallin, a pterocarpene from Erythrina mildbraedii,” *European Journal of Pharmacology*, vol. 468, no. 1, pp. 67–74, 2003.

[170] V. R. Hegde, P. Dai, M. G. Patel et al., “Phospholipase A2Inhibitors from anErythrinaSpecies from Samoa,” *Journal of Natural Products*, vol. 60, no. 6, pp. 537–539, 1997.

[171] P. Mandal, T. K. Misra, and M. Ghosal, “Blume Free-radical scavenging activity and phytochemical analysis in the leaf and stem of Drymaraia diandra Blume,” *International Journal of Integrative Biology*, vol. 7, no. 2, pp. 80–84, 2009.

[172] S. Kumar, A. S. Pathania, A. K. Saxena, R. A. Vishwakarma, A. Ali, and S. Bhushan, “The anticancer potential of flavonoids isolated from the stem bark of Erythrina suberosa through induction of apoptosis and inhibition of STAT signaling pathway in human leukemia HL-60 cells,” *Chemico-Biological Interactions*, vol. 205, no. 2, pp. 128–137, 2013.

[173] S. Y. Pan, S. F. Zhou, S. Gao et al., “New perspectives on how to discover drugs from herbal medicines: CAM’s outstanding contribution to modern therapeutics,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2013, Article ID 627375, 25 pages, 2013.

[174] S. Irungu, “Isolation and characterization of antimicrobial compounds from the plants, Erythrina abyssinica DC. and Chasmanthera Dependens Hochst.” M.Sc. thesis, Kenyatta University, Nairobi, Kenya, 2012.

[175] W. Chitopoa, I. Muchachaa, and R. Mangoyi, “Evaluation of antimalarial activity of Cluitia abyssinica and Erythrina abyssinica plants extracts used among the Kipsigis community of Bomet district in Kenya,” *South African Journal of Botany*, vol. 87, no. 4, pp. 1–5, 2019.

[176] W. Chitopoa, I. Muchachaa, and R. Mangoyi, “Evaluation of antimalarial activity of Cluitia abyssinica and Erythrina abyssinica plants extracts used among the Kipsigis community of Bomet district in Kenya,” *European Journal of Medicinal Plants*, vol. 27, no. 4, pp. 1–5, 2019.

[177] M. Mariita, *Efficacy of Medicinal Plants Used by Communities Around Lake Victoria Region and the Samburu against Mycobacteria, Selected Bacteria and Candida Albicans*, Kenyatta University, Nairobi, Kenya, 2011.
[178] Q. Tan, J. Ni, P. Fang, and Q. Chen, “A new Erythrinan alkaloid glycoside from the seeds of Erythrina crista-galli,” Molecules, vol. 22, no. 1558, pp. 1–7, 2017.

[179] S. Djiogue, M. Halabalaki, D. Njamen et al., “Erythroidine alkaloids: a novel class of phytoestrogens,” Planta Medica, vol. 80, no. 11, pp. 861–869, 2014.

[180] N. M. Fahmy, E. Al-sayed, M. El-shazly, and A. Nasser Singab, “Alkaloids of genus Erythrina: an updated review,” Natural Product Research, vol. 34, no. 13, pp. 1891–1912, 2020.

[181] D. Santos Rosa, S. A. Faggion, A. S. Gavin et al., “Erysothrine, an alkaloid extracted from flowers of Erythrina mulungu Mart. ex Benth: evaluating its anticonvulsant and anxiolytic potential,” Epilepsy & Behavior, vol. 23, no. 3, pp. 205–212, 2012.

[182] M. A. R. Serrano, A. N. L. Batista, V. S. Bolzani et al., “Anxiolytic-like effects of erythrinian alkaloids from erythrina suberosa,” Quim Nova, vol. 34, no. 3, pp. 808–811, 2011.

[183] A. Marume, G. Matope, S. Katsande et al., “Wound healing properties of selected plants used in ethnoveterinary medicine,” Frontiers in Pharmacology, vol. 8, p. 544, 2017.

[184] OECD, “OECD guideline for testing of chemicals: acute oral toxicity—acute toxic class method,” OECD Guideline for Testing of Chemicals, 2001.

[185] A. Maroyi, “Garden Plants in Zimbabwe: their ethnomedicinal uses and reported toxicity,” Ethnobotany Research and Applications, vol. 10, pp. 45–57, 2012.